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CHAPTER I 
 
INTRODUCTION 
Statement of the Problem  
 Depression in pregnancy is a serious and growing problem affecting 8-27% of 
women worldwide (CDC, 2007; Bansil et al., 2010; Gaynes et al., 2005; Ko, Farr, Dietz, 
& Robbins, 2012; NSDUH 2012; Villegas, McKay, Dennis, & Ross, 2011). A woman 
experiencing depression during her pregnancy is at increased risk for pregnancy 
complications. She is also at higher risk for inter-relational conflict with her partner that 
may include partner violence (Roberts, Bushnell, Collings, & Purdie, 2006). Maternal 
depression during pregnancy also places the developing fetus at risk for complications 
(2004-2006 NHIS; Milgrom et al., 2008; Pilowsky, 2008; Pesiah et al., 2004; Weissman 
et al., 2006). The disease burden of depression in pregnancy leads to increased healthcare 
costs and negative sequelae for society, healthcare, and individuals (Lin, Lin, Hsiao, & 
Li, 2009; Pesiah et al., 2004; Seto et al., 2005; WHO, 2012).   
 Potentially compounding the development of depression in pregnancy are 
low levels of Vitamin D. Growing evidence suggests that many pregnant women have 
low vitamin D levels despite taking prenatal vitamins (Brannon & Piccano 2011; Bodnar 
et al., 2007; Holmes et al., 2009; Marwaha et al., 2011). Vitamin D deficiency may be an 
important risk factor for depression in pregnancy (Brandenbarg, Vrijkotte, Goedhart, & 
van Eijsden, 2012; Cassidy-Bushrow, Peters, Johnson, Li, & Rao, 2012), but this 
evidence remains inconclusive (Nielsen et al., 2013). In order to further the science in 
this area, this dissertation study was undertaken to examine the longitudinal association 
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between depressive symptoms and vitamin D in a sample of pregnant women. An 
overview of depression in pregnancy and vitamin D deficiency, the significance of these 
problems individually and collectively and the purpose of the study is presented below.  
 
Definition of Terms 
Depression 
Globally, depression is the leading cause of disability with over 350 million 
people suffering worldwide (WHO, 2012). Untreated depression can lead to suicide, 
which accounts for 1 million lives lost each year (WHO, 2012). Women are more likely 
than men to be affected by depression with depression being the most common mental 
disorder in women (WHO, 2012). Depression affects approximately 1-2 out of every 10 
mothers within the first year after giving birth (Banti et al., 2011; WHO, 2012).  
Depression in pregnancy increases the risk for pregnancy complications (2004-
2006 NHIS; Milgrom et al., 2008; Pilowsky, 2008), may heighten the potential for inter-
relational conflict increasing the partner’s risk for mental disorders and violence  
(Roberts, Bushnell, Collings, & Purdie, 2006) and creating increased healthcare costs 
(Lin, Lin, Hsiao, & Li, 2009). In addition, depression in pregnancy has been associated 
with impacts on the developing fetus such as later cognitive and behavioral disabilities 
(Pesiah et al., 2004; Weissman et al., 2006). Depression is a syndrome characterized by 
depressed mood and psychomotor agitation for more than 2-weeks with impairment in 
functions of daily living (Pratt & Brody, 2008; U.S. Department of Health and Human 
Services (HHS), 2007; Kendall, Hollon, Beck, Hammen, & Ingram, 1987). Symptoms of 
depression may include the following: sad feelings, fatigue, sleep disturbances, changes 
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in appetite, physical pain, trouble focusing, and an inability to enjoy pleasant activities 
(NIMH, 2008).  
Timing of depression can vary in the perinatal period, with onset in the antenatal 
period, occurring in pregnancy prior to giving birth, or during the postpartum period for 
up to 12 months after giving birth (Gaynes et al., 2005). Antenatal depression may be 
phenotypically different from depression that has its onset in the postpartum period 
(Altemus et al., 2012).  Women who experience depression in pregnancy are more likely 
to cite poor social support, abuse, an unplanned pregnancy, to have a history of 
depression, and to have recently stopped taking antidepressants (Altemus et al., 2012; 
Mora et al., 2009; Stowe, Hostetter, & Newport, 2005). Women with depression onset 
postpartum are more likely to be experiencing their first episode of depression, to cite 
infant medical problems as a stressor, and to suffer severe features such as intrusive 
violent thoughts and psychosis (Altemus et al., 2012; Mora et al., 2009; Stowe et al., 
2005).  There are, however, no differences in rates of suicidal ideation during the two 
time periods (Altemus et al., 2012). Despite potential mechanistic differences antenatal 
and postpartum depression are highly correlated (Milgrom et al., 2008) and 
comprehensive meta-analysis findings suggest that the incidence in both periods is 
approximately the same (Gaynes et al., 2005).  
Along with timing, the severity of depression can vary from mild to severe. Mild 
depression is characterized by the presence of depressive symptoms but does not meet the 
standard criteria for major depression (Gaynes et al., 2005). Major depression as defined 
by DSM-IV-TR criteria is the demonstration of specific depressive symptoms with 
regularity and significant impairment for at least 2 weeks (APA, 2000).  Severe 
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depression is major depression that is causing severe impairment (e.g., catatonia) and that 
may develop into psychotic depression (Gaynes et al., 2005). Since the primary interest in 
depression is its relationship to vitamin D, all forms of depression are relevant to better 
understanding this link.  
Several risk factors for depression in pregnancy have been identified in previous 
studies. These include: anxiety, life stress, history of depression, unplanned pregnancy, 
inadequate social support, domestic violence (Bunevicius et al., 2009; Lancaster et al., 
2010; Milgrom et al., 2008; O’Hara, 1986), financial stress (Grote & Bledsoe, 2007), 
obesity, low educational attainment, poverty, a history of poor obstetrical outcome 
(Lancaster et al., 2010; Murphy, Mueller, Hulsey, Ebeling, & Wagner, 2010), obesity, 
and physical inactivity (Shivakumar et al., 2010). Recent evidence also suggests that 
underlying inflammation may be an important risk factor and possible biological 
mechanism for depression in pregnancy (Blackmore et al., 2011; Cassidy-Bushrow et al., 
2012; Christian et al., 2009; Leonard & Maes, 2012; Maes, Ruckoanich, Chang, 
Mahanonda, & Berk, 2011). Despite growing knowledge on risk factors for depression in 
pregnancy preventative interventions have not been identified and the problem is 
growing.  
Over the last decade, rates of maternal depression have been on the rise.  In a 
large study of 32,156,438 hospital deliveries, the rate of maternal depression increased 
from 2.73 per 1,000 deliveries in 1998 to 14.1 per 1,000 deliveries in 2005 (p < 0.001) 
(Bansil et al., 2010). Some posit that the rising rates of depression may be linked to an 
emerging modern lifestyle (Hidaka, 2012). Recent years have seen advances in the 
maternal age of pregnant women (Mathews & Hamilton, 2009), increased fatigue 
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(National Sleep Foundation, 2009), higher rates of obesity (Orelind et al., 2012), more 
sedentary lifestyles (Gerdhem et al., 2005; Jorde et al., 2008), and increased social 
isolation (McPherson et al., 2006; Hidaka, 2012). For many women, current lifestyle has 
led to decreased time spent outside, increased sunscreen use, and increased exposure to 
pollutants (Agarwal et al., 2002; Hosseinpanah et al., 2010) resulting in a decrease of 
their bodies’ ability to synthesize vitamin D. Current literature suggests that low vitamin 
D levels may increase the risk for depression in pregnancy and thus may explain some of 
the rise in the incidence of depression in pregnancy (Brandenbarg et al., 2012; Brannon & 
Picciano, 2011; Cassidy-Bushrow et al., 2012; Murphy et al., 2010; Robinson et al., 
2014). But this relationship is not clearly established (Nielsen et al., 2013).  
 
Vitamin D 
Vitamin D is both a nutrient and a pro-hormone (Institute of Medicine (IOM), 
2011) synthesized in the skin as a result of exposure to sunlight. Skin cells make 7-
dehyrdocholesterol. When these cells are exposed to sunlight 7-dehyrocholesterol is 
converted to vitamin D3 (Glossmann, 2010).  Along with synthesis in the skin, vitamin D 
is found in some foods and animal products. A synthetic, fat-soluble form can be taken as 
a supplement or through fortified foods (e.g., milk).  Vitamin D3 is the form made within 
the body as a result of exposure to sunlight, and vitamin D2 is historically thought of as 
the supplemental form; however supplementation with D2 is phasing out and most foods 
and supplements today contain D3. Despite the availability of supplements and fortified 
foods, adequate amounts of vitamin D cannot be achieved through supplementation 
alone. Endogenous vitamin D through exposure to sunlight is critical (IOM, 2011).  
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Vitamin D3 and vitamin D2 are metabolized in the same way and are both useful at 
equal doses for treating vitamin D deficient disease (e.g. rickets) (IOM, 2011; Jurutka et 
al., 2001). Both forms of vitamin D are initially biologically inactive and are transformed 
into their active forms through two hydroxylations. The first takes place in the liver 
converting both endogenous and exogenous forms of vitamin D to 25-hydroxyvitamin D 
(25OHD). The second hydroxylation takes place primarily in the kidneys where 1α-
hydroxylase catalyzes conversion of 25OHD to its active form 1,25 dihydroxyvitamin D 
[1,25(OH)2D] also known as calcitrol. Calcitrol production is increased by the up 
regulation of parathyroid hormone (PTH) and low levels of serum phosphorus, and 
decreased by fibroblast-like growth factor-23 (FGF23) (Bergwitz and Juppner, 2010; 
Galitzer et al., 2008; IOM, 2011; Prie & Friedlander, 2010).  Calcitrol exerts its 
biological actions by binding to vitamin D receptors (VDRs) located throughout the body 
(IOM, 2011; Jones et al., 1998).  Figure 1 depicts vitamin D synthesis and uptake (IOM, 
2011). 
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Figure 1. Overview of vitamin D synthesis and uptake 
 
(IOM, 2011) 
 
The interaction between calcitrol and VDRs plays an important role in the up 
regulation of cathelicidin an antimicrobial peptide (Borella, Nesher, Israeli, & Shoenfeld, 
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2014).  Vitamin D has been found to have a role in T cell regulation and other 
immunomodulating pathways (van Etten & Mathieu, 2005). However a recent study of 
young vitamin D deficient women (N=131) noted no increase in mRNA expression of 
cathelicidin after 6 months of vitamin D supplementation (Das, Tomar, Sreenivas, Gupta, 
& Goswami, 2014).  Much still remains to be discovered about the role of vitamin D in 
immunity.  
Beyond immunity, the primary biological action of vitamin D is maintaining a 
balance of calcium and phosphorous in the body, thus protecting skeletal health. 
However, vitamin D may have many other functions within the body and its function has 
been implicated in both immune system regulation (as noted above) and cell production 
(Adams & Hewison, 2010; Hayes et al., 2003; IOM, 2011). Vitamin D has been 
implicated in brain function (Harms et al., 2011; Kesby et al., 2011; Eyles et al., 2009) 
and vitamin D receptors have been found in neurological tissue (Jones et al., 1998). 
Vitamin D may also have an important role in pregnancy as VDRs have been found in 
ovarian, mammary, and placental tissue and vitamin D has been shown to affect fertility 
in animal models (Jones et al., 1998). 
 Since the primary source of vitamin D is endogenous synthesis through skin 
exposure to sunlight, risk factors for vitamin D include anything that inhibits this process.  
Proper sunscreen use (Matsuoka, Ide, Wortsman, MacLaughlin & Holick, 1987) and dark 
skin pigmentation (Clemens, Adams, Henderson, & Holick, 1982) can independently 
reduce synthesis of vitamin D by as much as 99% (Holick & Chen, 2008). Older adults 
are also at increased risk for vitamin D deficiency because of decreases in levels of 7-
dehyrdocholesterol with advancing age (Holick, 2007). Similar to depression, obesity has 
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been linked to a vitamin D deficiency. Vitamin D is fat-soluble and can be sequestered by 
large stores of fat (adipose) cells (Wortsman, Matsuoka, Chen, Lu, & Holick, 2000). In 
addition anticonvulsant and anti-retroviral use (Zhou et al., 2006) has been linked to 
vitamin D deficiency due to their catabolic action on 25OHD. Some forms of cancer (e.g. 
lymphoma) (Adams & Hewison, 2006) and hyperparathyroidism can lead to vitamin D 
deficiency due to accelerated metabolism of 25OHD to calcitrol (Grey et al., 2005). As 
previously described a modern lifestyle may help explain why vitamin D deficiency 
remains an important public health issue and is relevant for pregnant women.  
 There is great debate about the incidence of vitamin D deficiency. The incidence 
of vitamin D deficiency in the form of childhood rickets dropped significantly in the 
1930s and 1940s with the fortification of milk (National Research Council, 2003; Quick 
& Murphy, 1982). However, as previously mentioned, risk factors for vitamin D 
deficiency persist. Current estimates of the incidence of low vitamin D in a perinatal 
population range widely from 5% to 84% (Brannon & Picciano, 2011). This wide range 
may be attributed to the ongoing debate about what level of vitamin D should be 
considered adequate. Despite debates on exact levels, the literature indicates that 
pregnant women have lower levels of vitamin D than non-pregnant women despite taking 
prenatal vitamins (Brannon & Piccano 2011; Bodnar et al., 2007; Holmes et al., 2009; 
Marwaha et al., 2011).  
 Studies also indicate low levels of vitamin D increase the risk for serious 
complications during pregnancy (Baker, Haeri, Camargo, Espinola, & Stuebe, 2010; 
Baker, Haeri, Camargo, Stuebe, & Boggess, 2012; Merewood, Mehta, Chen, Bauchner, 
& Holick, 2009; Ota et al., 2014), and negatively impact the health and development of 
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children born to vitamin D deficient mothers (Belderbos et al., 2011; Camadoo, Tibbott, 
& Isaza, 2007; Kalra et al., 2012; McGrath, Burne, Feron, Mackay-Sim, & Eyles, 2010). 
A better understanding of the association between vitamin D and depression in pregnancy 
may be the key to reducing risk, developing effective interventions, and improving birth 
and postpartum outcomes for women and children.  
 
Significance of Depression and Vitamin D Deficiency in Pregnancy 
The negative impact of depression and vitamin D deficiency in pregnancy extends 
to society, individuals, healthcare, and nursing. As a society we see the effects of 
depression and vitamin D deficiency in pregnancy by the impaired ability of women, 
their children, and their partners to contribute to society, coupled with the financial 
weight of disability (Grant, 2011; Grant, Schwalfenberg, Genuis, & Whiting, 2010; 
Murray et al., 2011; Seto et al., 2005; Stewart, Ricci, Chee, Hahn, & Morganstein, 2003; 
WHO, 2008). Depression in pregnancy is significant to both healthcare and nursing 
because it leads to great disease burden and increased healthcare costs (Bansil et al., 
2010; Berto, D’Ilario, Ruffo, Di Virgilio, & Rizzo, 2000; Greenberg et al., 2003; Kalra et 
al., 2012; WHO, 2012). Nurses are poised to take an important role in emerging research 
about vitamin D deficiency and depression in pregnancy and in raising awareness and 
improving treatment. A review of the significance of depression in pregnancy is critical 
to understanding the need for further research in this field. 
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Significance to Society 
Perinatal depression has been brought to the social forefront through public 
personas like Brittany Spears and horrific tragedies such as the case of Andrea Yates. 
These cases have spawned national attention and social responses to depression in 
pregnancy and postpartum such as charities and help lines. Funding for screening and 
care of women with postpartum depression was included in the Patient Protection and 
Affordable Care Act as part of the March 2010 health reform legislation.  
Despite growing social awareness only about 4 out of 10 women with perinatal 
depression receive treatment (Witt, 2009). In general women who do not receive 
treatment for their depression may be more likely to be divorced, have lower incomes, 
less education, higher substance abuse disorders, and more financial problems (Seto et 
al., 2005). Not only does perinatal depression have negative influences on women, but 
also partners of women with depression have a higher incidence of depression, 
aggression, and other psychological problems (Roberts, Bushnell, Collings, & Purdie, 
2006).  
Children of depressed mothers are at risk for experiencing negative sequelae to 
their health and psychological well-being.  Longitudinal studies of children born to 
mothers with depression found that these children display higher incidences of anxiety 
disorders, substance abuse, disruptive behaviors, and psychological diagnoses (Pesiah et 
al., 2004; Weissman et al., 2006) as compared to children of mothers without depression. 
Higher depressive symptoms during the perinatal period have been associated with 
cognitive disability (Sohr-Preston & Scaramella, 2006), poor language development 
(Stein, Malmberg, Sylva, Barnes, & Leach, 2008), autisim (Rai et al., 2013), and a 
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greater incidence of  mental illness later in life (Murray et al., 2011). Perinatal depression 
not only affects the development of healthy members of society, it clearly impairs those 
who are suffering. Depression generally costs about $83.1 billion dollars annually. Of 
this $51.5 billion dollars is due to lost productivity of those individuals with depression 
as compared to those without depression (Stewart, Ricci, Chee, Hahn, & Morganstein, 
2003).  
Similar to depression, low levels of vitamin D have significant impact on society.  
The World Health Organization (WHO) notes that vitamin D deficiency may be linked to 
diseases associated with up to 67% of the annual deaths for women globally (Grant, 
2011; WHO, 2008).  In children, low vitamin D levels have long been known to cause 
rickets (IOM, 2011) whereas in adults low vitamin D levels have been linked to an 
increased risk for fractures (Cummings et al., 2005; IOM, 2011), falls (Flicker, 2003; 
Sambrook et al., 2004), diabetes (Brock et al., 2011), cancer (Lappe et al., 2007; 
Wactawski-Wende et al., 2006), and depression (Hoogendijk et al., 2008; Jorde et al., 
2008). 
 
Significance to Healthcare 
Depression and vitamin D deficiency are very significant issues within our health 
care delivery system and present many challenges to the care of pregnant women.  
Depression in pregnancy has been associated with a caesarean delivery, preterm birth 
(Staub et al., 2012), anemia, diabetes, preeclampsia (Bansil et al., 2010), infant death, low 
birth weight, and congenital malformations (2004-2006 NHIS; Schneid-Kofman et al., 
2007). Perinatal depression represents a unique challenge to the healthcare community 
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because it often negatively affects innate defenses, causes worsening of other illnesses 
(Pratt & Brody, 2008), and may prevent patients from taking an active role in their 
healthcare due to the inherent feelings of helplessness or apathy in a depressed patient.  
The American College of Obstetrics and Gynecology (ACOG) strongly 
encourages obstetrical providers to screen women during and after pregnancy for 
depression (ACOG, 2010). However on average less than half of women in the perinatal 
period are screened and even fewer practitioners report using validated screening tools 
(Delatte et al., 2009; Hatton et al., 2007). As a result many cases of depression in 
pregnancy go undetected and untreated (Delatte et al., 2009; Hatton et al., 2007). This is 
despite current evidence suggesting that pregnant women choose treatment as much as 
93.4% of the time when treatment is offered to them (Dietz et al., 2007).  
Anti-depressants are the most commonly used treatment for depression in the U.S. 
(Lawrence et al., 2012). Unfortunately, use of anti-depressants in pregnancy may increase 
the risk for miscarriage (Kjaersgaard et al., 2013; Nakhai-Pour et al., 2010; Nikfar et al., 
2013), lower birth weights (Klieger-Grossmann et al., 2011; Ross et al., 2013), preterm 
birth (Wisner et al., 2009), persistent pulmonary hypertension (PPH) of the newborn 
(Grigoriadis et al., 2014; t Jong, Einarson, Koren, & Einarson, 2012), and autism (Rai et 
al., 2013). However, research on comorbidities and anti-depressant use in pregnancy is 
limited. Further studies are needed to validate these associations. The need for more 
research to improve understanding of risk factors and underlying mechanisms to facilitate 
early identification and safe effective therapy for perinatal depression is great. 
The presence of depression can significantly complicate and heighten the level of medical 
care needed for these women, which often results in significant medical costs.  Estimates 
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suggest that prenatal care costs for women with depression may be increased by as much 
as 44% (Lin et al., 2009) and postpartum costs may increase by almost 20% as compared 
to women without depression (Petrou, Cooper, Murray, & Davidson, 2002). Limited 
information is available related to specific healthcare costs for perinatal depression, 
however it has been estimated that the U.S. spends approximately $26.1 billion in direct 
healthcare costs for depression; 67% of these costs are accounted for by hospitalization 
and $5.4 billion are suicide-related (Berto, D’Ilario, Ruffo, Di Virgilio, & Rizzo, 2000; 
Greenberg et al., 2003). A more recent report by the WHO noted that general depression 
represents about 4.4% of the global disease burden, on par with the impact of diarrheal 
illnesses and ischemic heart disease (WHO, 2012; Chisholm, Sanderson, Ayuso-Mateos, 
& Saxena, 2004).  
The impact of vitamin D deficiency in pregnancy on healthcare is evidenced by 
an increased risk for miscarriage (Ota et al., 2014), anemia (Bener, Al-Hamaq, & Saleh, 
2013), pre-eclampsia (Baker et al., 2010; Bener et al., 2013; Haugen et al., 2009; C. J. 
Robinson, Alanis, Wagner, Hollis, & Johnson, 2010; C. J. Robinson, Wagner, Hollis, 
Baatz, & Johnson, 2013), the development of gestational diabetes (Baker et al., 2012; 
Bener et al., 2013; Ramos-Lopez et al., 2008; Soheilykhah, Mojibian, Rashidi, Rahimi-
Saghand, & Jafari, 2010; Zhang et al., 2008), and primary cesarean delivery (Merewood 
et al., 2009). However, studies investigating these associations are limited and 
inconclusive.  For example, some study findings do not show a significant correlation 
between low vitamin D and gestational diabetes (Farrant et al., 2009) or pre-eclampsia 
(Powe et al., 2010; Shand, Nassar, Von Dadelszen, Innis, & Green, 2010).  
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Neonates born to mothers with low vitamin D levels may be at increased risk for 
respiratory syncytial virus (Belderbos et al., 2011), childhood asthma (Devereux et al., 
2007), schizophrenia (McGrath et al., 2010), hypocalcemic seizures (Camadoo et al., 
2007), congenital rickets (ACOG, 2011; Bodnar et al., 2007; Dijkstra et al., 2007), and 
infant heart failure (Maiya et al., 2008). Not only do low levels of maternal vitamin D 
increase infant morbidities, but vitamin D supplementation in pregnancy, in addition to 
prenatal vitamins, has been associated with greater infant birth weight, length, and head 
circumference (Kalra et al., 2012), and higher one and five minute APGAR scores 
(Hossain et al., 2014).  
In light of the negative role that vitamin D deficiency plays in pregnancy and 
infant development it has been estimated that treatment of vitamin D deficiency could 
reduce obstetrical healthcare costs by 10% or more (Grant, Schwalfenberg, Genuis, & 
Whiting, 2010). In 2004 Grant et al. (2005) estimated the economic burden for vitamin D 
deficiency in the U.S. was approximately $40-56 billion annually (Grant, Garland, & 
Holick, 2005). More recent literature indicates that economic burden resulting from 
vitamin D deficiency could be reduced by 6.9% or $14.4 billion dollars by increasing 
vitamin D levels in Canada (Grant et al., 2010). 
 
Significance to Nursing 
Depression in pregnancy holds particular significance for nursing the largest 
healthcare occupation in the U.S. accounting for 2.6 million jobs nationally (U.S. Labor 
Department, 2009). National nursing organizations clearly recognize the significance of 
depression. Major national nursing organizations such as the Association of Women’s 
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Health, Obstetric, and Neonatal Nurses (AWHONN) and the American College of Nurse-
Midwives (ACNM) have position statements that support the role of nurses in the 
prevention, screening, education, and treatment of women with depression or postpartum 
mood disorders and call for further research to better understand these phenomena 
(AWHONN, 2008; ACNM, 2003).  
In addition, findings from studies of nurses underscore the potential and actual 
roles of nurses. For example, in a survey of 520 nurses assessing their perception of 
nursing roles in postpartum depression care, 93.7% of the respondents agreed that nurses 
should have a role in postpartum depression screening and treatment (Segre et al., 2010). 
Better understanding of perinatal depression is not only significant to nursing in these 
specific ways, but it is also represented in nursing’s overall goal to prevent illness, 
optimize health, and secure treatment for those who are ill (ANA, 2003). Societal and 
healthcare impacts of depression in pregnancy are immense and warrant greater effort 
towards intervention development on the part of the scientific community. 
As previously noted the profession of nursing is large and well situated, although 
perhaps unequipped, to educate pregnant women about the risks of vitamin D deficiency 
as well as depression. Recent research investigating the association between depression 
and vitamin D in pregnancy includes both nurses and nurse-midwives (Cassidy-Bushrow 
et al., 2012; Murphy et al., 2010).  However, one study that surveyed nurses and 
midwives conducting community health visits in the United Kingdom showed that only 
52% were aware of current recommendations for vitamin D supplementation (Locyer, 
Porcellato, Gee, 2011).  With the important role that nurses play in research, education, 
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and public health more efforts are needed to involve the profession of nursing with the 
issue of vitamin D deficiency in pregnancy.  
 
Purpose of the Study 
Depression in pregnancy and vitamin D deficiency are serious diseases with 
widespread implications for society and science. Research suggests shared risk factors 
and inflammatory mechanisms in both depression and vitamin D deficiency. Learning 
more about the association between depressive symptoms and vitamin D levels in 
pregnancy may increase our understanding of the mechanisms underlying these diseases. 
If vitamin D deficiency can be identified as a risk factor for depression in pregnancy then 
this may be an important step towards early identification and prevention of depression 
among women in pregnancy and beyond. In order to further the science in this area, this 
dissertation study was undertaken to examine associations between depressive symptoms 
and vitamin D levels in a sample of women during the course of their pregnancy. The 
following research questions and hypothesis guided the study:  
 
Research Questions 
1. Is there a difference between early and late pregnancy vitamin D levels?  
2. Is there a difference between early and late pregnancy depressive symptoms?  
3. Is there a relationship between vitamin D levels and depressive symptoms during 
pregnancy?  
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Hypothesis 
There is an inverse association between vitamin D and depressive symptoms in 
this sample of pregnant women. As vitamin D levels decrease, depressive symptoms will 
increase during pregnancy.  
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CHAPTER II 
 
 
LITERATURE REVIEW AND THEORETICAL FRAMEWORK 
 
 In an effort to further understand the association between vitamin D and 
depression a review of relevant literature was conducted. Knowledge derived from the 
literature was used to construct a theoretical framework for describing hypothesized 
associations between depression and vitamin D in pregnancy. An understanding of 
current literature and a theoretical framework were used to develop this dissertation 
study, which explored associations between vitamin D and depression in pregnancy.  
 
Historical Perspective 
The hypothesis and study of a relationship between vitamin D and depression is a 
more recent phenomenon than the study of the individual illnesses. Depression predates 
vitamin D in historical literature.  Hippocrates describes depression or melancholy humor 
as a prolonged “fright or despondency” in his Aphorisms from approximately 400 BC 
(Hippocrates, 400 BC). He also wrote about depression as it relates to the pregnant 
woman describing postpartum depression as “puerperal fever,” believing that 
unexpressed bodily fluids were being shunted to the head and causing mood changes in 
the woman (Thurtle, 1995). Currently, both postpartum and antenatal depression though 
widely acknowledged are not defined as unique diagnoses from general major depression 
in the DSM-IV-TR (APA, 2000), but the timing of the depression as occurring after birth 
or during pregnancy can be specified when the diagnosis is confirmed. 
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Soranus of Ephesus may have been the first to describe vitamin D deficiency in 
the form of “distorted limbs” and “weak bones” (rickets) in 1st and 2nd Century A.D. 
(Soranus & Temkin, 1956).  An early perinatologist, he attended the famous medical 
school in Alexandria and noted that this condition of bone deformities was particularly 
common in Rome, as compared to Greece, and attributed it to premature weight bearing 
and poor maternal care of infants (Soranus & Temkin, 1956).  However, rickets was not 
formally described until 1645 by Daniel Whistler in his medical school dissertation. It 
was more thoroughly detailed by Francis Glission in his Latin treatise  “De Rachitide” 
later in 1650 (Hess, 1929; Ruhrah, 1925). Then in 1919 Sir Edward Mellanby found that 
giving cod liver oil to dogs raised without exposure to sunlight prevented the 
development of rickets and noted that this must be due to a “vitamin” the dogs lacked in 
their diets (Mellanby & Cantag, 1919). In 1922 E.V. McCollum et al. separated vitamin 
A from vitamin D (McCollum, Simmonds, Becker & Shipley, 1922) and in 1923 
Goldblatt and Soames discovered that skin exposed sunlight synthesized “a fat soluble 
vitamin”, vitamin D (1923).  
Early theories on a relationship between depression and vitamin D perhaps began 
with Hippocrates who noted in 400 BC that seasonal changes often lead to the 
development of disease (Hippocrates, 400 BC). Later, in 200 AD, the Greek physician 
Aretaeus wrote on a possible link between mood and vitamin D, noting ‘lethargics are to 
be laid in the light and exposed to the rays of the sun (for the disease is gloom)’(Aretaeus 
& Adams, 1856).  The potential immunomodulating and anti-bacterial properties of 
vitamin D have been noted since the turn of the century as tuberculin patients were often 
treated in open air sanatoriums with “sunbaths” and “heliotherapy” and marked 
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improvement was noted as compared to traditional treatments (Cook, 1999; Kibler & 
Watson, 1935). Most of the research supporting a possible link between vitamin D and 
depression within pregnancy has been conducted within the last 5-10 years (Brandenbarg 
et al., 2012; Cassidy-Bushrow et al., 2012; Murphy et al., 2010; Nielsen et al., 2013; M. 
Robinson et al., 2014).  A detailed review of current and associated literature follows. 
 
Literature Review 
Current literature related to vitamin D and depressed mood were reviewed.  
Included in the review of the literature were studies examining relationships between the 
following: vitamin D and seasonal affective disorder (SAD), vitamin D and depression or 
depressive symptoms in non-pregnant populations, and randomized controlled trials that 
evaluated vitamin D supplementation in pregnant women.  This synthesis of literature 
provides a helpful context for understanding the current state of the science related to 
between vitamin D and depression/depressive symptoms in the perinatal period.  
 
Vitamin D and SAD 
Several studies have explored the relationship between levels of vitamin D and 
SAD in a variety of populations. All of the studies reviewed involving SAD were 
prospective in design and interventional in nature, assessing for improvement in mood 
and/or vitamin D levels following treatment with light and/or vitamin D supplementation 
(Dumville et al., 2006; Gloth et al., 1999; Harris& Dawson-Hughes, 1993; Oren et al., 
1994; Partonen et al., 1996).  Overall, findings from these studies did not support a 
relationship between vitamin D and SAD. For example, Dumville et al. randomized 1621 
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elderly women to either take 800 IU of vitamin D daily or receive an educational handout 
(2006). Level of depressive symptoms was measured at baseline and again 6 months 
later. There were no significant differences between the two groups (p=0.262) (Dumville 
et al., 2006). However, the researchers did not measure vitamin D levels in their sample 
prior to or after supplementation, a major limitation in trying to understand if the women 
in the treatment group were more or less deficient than the women not receiving 
treatment, or if supplementation successfully raised their vitamin D levels. Current 
research indicates that in order to significantly raise blood levels of vitamin D 
participants must take approximately 2,000 international units (IU) of Vitamin D daily 
for a least one month (Hollis et al., 2011). 
Methodological issues limited many of the studies exploring interactions between 
vitamin D and SAD. In addition non-random designs, small sample sizes, and low levels 
of supplementation (e.g. ≤ 800 IU of vitamin D) were commonly used (Dumville et al., 
2006; Gloth et al., 1999; Harris& Dawson-Hughes, 1993; Oren et al., 1994; Partonen et 
al., 1996).  The only study with findings supporting an association between level of 
depressive symptoms and vitamin D levels (i.e., a decrease in depressive symptoms was 
significantly correlated with increased vitamin D levels of those with SAD), tested 
vitamin D supplementation of 100,000 IU over the course of a month (Gloth et al., 1999). 
A major limitation of this study was the small sample size (n=15). Given the numerous 
methodological issues noted above, the association between vitamin D levels and SAD 
seems probable but remains inconclusive. 
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Vitamin D and Depression In Non-Pregnant Populations 
 Studies that specifically examined depression and vitamin D in a non-pregnant 
population were reviewed (Eskandari et al., 2007; Hoang et al., 2011; Hoogendijk et al., 
2008; Jorde et al., 2008; Wilkins et al., 2006). For example, Jorde et al., randomized 
overweight men and women to two groups, either receiving a placebo or receiving 
vitamin D supplementation (20,000 IU and 40,000 IU/week). Participants were followed 
for one year to assess levels of depressive symptoms (2008). Investigators observed 
increases in vitamin D levels and decreases in depressive symptoms as compared to the 
placebo group (p<0.05; Jorde et al., 2008). Similarly, in a large population based study 
(n=1,282), researchers found vitamin D levels were 14% lower in participants with a 
depression diagnosis as compared to those without (p<0.01; Hoogendijk et al., 2008). 
Findings from a study of premenopausal women (N=116) indicated depressed women 
had lower vitamin D levels of as compared to non-depressed women  (25OHD 27 vs. 34 
ng/ml; p=0.002; Eskandari et al., 2007). Confirming this association was a noted increase 
in depressive symptom sum scores on the Beck Depression Inventory (BDI) (Beck, 
Ward, Mendelson, Mock, & Erbaugh, 1961) among older adults with vitamin D 
deficiency (OR: 11.69, p=0.02; Wilkins et al., 2006). From these studies, a probable 
association between depression/levels of depressive symptoms and vitamin D levels has 
been established.  
 
Vitamin D Supplementation In Pregnancy 
Relevant literature assessing associations between vitamin D and depression in 
pregnancy and postpartum periods were reviewed; including four randomized controlled 
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trials (RCTs) examining the outcomes of supplementation of vitamin D in pregnancy 
(Dawodu et al., 2013; Hossain et al., 2014; Mallet et al., 1986; Wagner et al., 2013).  
None of these RCTs measured depression or depressive symptoms of participants 
(Dawodu et al., 2013; Hossain et al., 2014; Mallet et al., 1986; Wagner et al., 2013). Two 
of the studies examined the safety and efficacy of supplementation with vitamin D of up 
to 4,000 IU a day in pregnancy (Hollis et al., 2011; Dawodu et al., 2013).  Both studies 
noted a significant rise in 25OHD levels in the 4,000 IU a day groups as compared to 
placebo groups and did not find any adverse effects of supplementation (Hollis et al., 
2011; Dawodu et al., 2013). Wagner et al. conducted a trial comparing two different 
levels of vitamin D supplementation. Women were randomized into two groups (N=200 
each group), one group of women received 2,000, IU of vitamin D and the second group 
received 4,000 IU of vitamin D. Women assigned to the 4,000 IU group tended to have 
fewer comorbidities, but the association did not reach statistical significance (Wagner et 
al., 2013). They did find that women with lower vitamin D levels (<32 ng/ml) had an 
increased incidence of comorbidities in pregnancy as compared to women with normal 
25OHD levels (67.3% vs. 55.3%, p=0.006; Wagner et al., 2013).  
Supplementation of women with vitamin D in RCTs has been found to be safe 
and effective at raising levels of vitamin D at high doses (e.g., 4,000 IU/daily). The 
impact of supplementation with vitamin D on pregnancy is difficult to assess in these 
RCT’s because vitamin D deficiency was not an inclusion factor in these studies and thus 
these studies do not assess treatment of vitamin D deficiency. None of the RCT’s 
examined depression or depressive symptoms.  
 
   
25 
Associations Between Depression and Vitamin D  
To date this author has identified five studies that examined the relationship 
between depression and vitamin D in the perinatal period (Brandenbarg et al., 2012; 
Cassidy-Bushrow et al., 2012; Murphy et al., 2010; Nielsen et al., 2013; M. Robinson et 
al., 2014). The studies can be clustered by the period during which the association was 
assessed: the pregnancy period (Brandenbarg et al., 2012; Cassidy-Bushrow et al., 2012), 
the postpartum period (Murphy et al., 2010), and the relationship of the pregnancy period 
to the development of depression or depressive symptoms postpartum (Nielsen et al., 
2013; M. Robinson et al., 2014).  
In a cross-sectional study, Cassidy-Bushrow and colleagues (2012) examined total 
25OHD levels and levels of depressive symptoms (using the Center for Epidemiologic 
Studies Depression Scale (CES-D)) in early pregnancy in a sample (N=178) of African 
American women. Study findings indicated a significant inverse association between 
25OHD and high depressive symptoms (CES-D scores ≥ 16) (adjusted OR 0.54, 95% 
confidence interval [CI] 0.29-0.99, p=0.046). This association remained stable even when 
controlling for age, education, marital status, and season. They evaluated a linear 
association and noted that for every 2.72 ng/mL increase in 25OHD, the odds for having 
a CES-D scores ≥ 16 decreased by 46% (Cassidy- Bushrow et al., 2012).  Several 
limitations were noted in this study and include: very high rates of vitamin D deficiency 
in their sample (82.6%) and physician prescribed supplementation, external to the study 
protocol, with vitamin D (50,000 IU/week 25OHD2) after time of 25OHD measurement 
in the study and prior to depression screening (Cassidy-Bushrow et al., 2012). 
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 In a larger nested cross-sectional study (N=4,101), the Amsterdam Born Children 
and Their Development Cohort Study, investigators observed an increased risk for high 
levels of depressive symptoms among pregnant with low first trimester 25OHD levels in 
the summertime (adjusted OR 1.66 (95% CI, 1.06-2.59), however this association was 
not significant during winter months (OR, 1.24; 95% CI, 0.86-1.78) (Brandenbarg et al., 
2012). Both studies conducted during the pregnancy period were limited by cross-
sectional designs, gaps in timing between measurements of vitamin D (3-11.4 weeks 
between measures), and homogenous samples (Brandenbarg et al., 2012; Cassidy-
Bushrow et al., 2012).  
Murphy et al. (2010) examined relationships between vitamin D and depression in 
the postpartum period. In their exploratory descriptive study, they used a longitudinal 
time series design to examine differences in mean depression scores among postpartum 
women (N=56) with low vitamin D as compared to postpartum women (N=41) with 
adequate levels. They noted that women with low vitamin D levels had higher depressive 
symptom scores (∆ =0.8 ±0.3, t (388) = 2.3, p = .02; N=97) (Murphy et al., 2010). These 
findings are limited by a convenience sample taking supplementation as part of a larger 
trial, exclusion of women with pre-existing diabetes, and exclusion of women whose 
infants were both breast and bottle-fed.  
Finally, two of the studies explored the association between vitamin D status in 
pregnancy and the development of postpartum depression (Nielsen et al., 2013; M. 
Robinson et al., 2014). Robinson et al (2014) conducted a secondary analysis of serum 
samples from Caucasian women (N=706) collected between 1989 and 1991 as part of the 
Western Australian Pregnancy Cohort.  They noted an association between low vitamin 
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D levels (<47nmol/L) at 18 weeks gestation and increased depressive symptoms at three 
days postpartum (prior to hospital discharge) (b=0.93, 95%CI = 0.27, 1.58). Women with 
vitamin D deficiency were more likely to experience elevated depressive symptoms as 
compared to women with higher (≥ 70 nmol/mL) vitamin D levels (OR= 2.19, 95%CI 
=1.26, 3.78) (Robinson et al., 2014). This study was limited by the large amount of time 
between measurements of vitamin D and screening for depression (~20 weeks), use of an 
abbreviated Edinburgh Postnatal Depression Scale, and measurement of depressive 
symptoms within the immediate postpartum period only.   
In contrast, Nielsen et al. (2013) in their retrospective case-control study of 
Danish women, 605 cases of women who filled prescriptions for anti-depressants within 
the first year of giving birth vs. 875 controls who did not, noted significant associations 
between both low (<49 nmol/mL) and high (>79 nmol/L) levels of vitamin D in 
pregnancy and postpartum anti-depressant use as compared to women with moderate 
levels of vitamin D (50-79 nmol/L; p = 0.08). However, the overall association between 
vitamin D levels in pregnancy and postpartum anti-depressant use was not significant 
(p=0.10) (Nielsen et al., 2013).  They noted that abnormally high levels of vitamin D 
might lead to degradation of the active form of vitamin D, 1,25(OH)2D, allowing for 
dysfunction of vitamin D-dependent brain processes leading to depression (Nielsen et al., 
2013).  
This study was limited by the case-control design (e.g., does not establish 
incidence, is unable to examine temporal precedence, and subject to sampling bias), and a 
lack of a standardized measure for assessing depression. The study designated case or 
control based on whether a prescription for antidepressants was filled in the first year 
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postpartum or not, but this fails to take into consideration depressed women who did not 
receive treatment and women taking anti-depressants for reasons besides depression 
(Nielsen et al., 2013). Other limitations included the exclusion of women with 
antidepressant use and mental illness prior to pregnancy, long gaps of time between 
measurement of vitamin D levels and depression, and a wide variation in gestational age 
at time of vitamin D measurement (Nielsen et al., 2013).   
An overview of studies that explored associations between depression/depressive 
symptoms and vitamin D in the perinatal period and its associated literature revealed only 
a small number of studies. Most notably, these studies were limited by their study 
designs, poor measurement techniques, timing of measures, sample selections and 
conflicting findings. A more detailed review of specific methodological issues in relevant 
literature exploring associations between depression/depressive symptoms and vitamin D 
in the perinatal period is provided below. 
 
Methodological Assessment  
A review of methods used in studies that investigated the relationship between 
vitamin D and depression in pregnancy is critical to a thorough understanding of this link. 
Key research methods reviewed were sample selection, study design, measures, and 
analysis techniques. This review was necessary to identify strengths in prior works, 
challenges to conducting related research and gaps in our understanding of 
methodological issues. Information gained from this review guided the development of 
this dissertation study.  
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Sample Selection 
Selecting a sample and choosing a setting are important steps in the research 
process. A review of samples and settings found in studies that examine the relationship 
between vitamin D and depression in pregnancy served to inform the development of the 
dissertation study.  Considering the range of studies reviewed, the largest sample noted 
was a nested cohort of 4,101 pregnant women in the Amsterdam Born Children and Their 
Development Cohort Study (Brandenbarg et al., 2012). The smallest sample noted was 97 
postpartum women in a longitudinal study examining vitamin D and depression in the 
postpartum period (Murphy et al., 2010). Given the difficulty of enrolling and retaining 
large prospective samples of pregnant women it is not surprising that the only available 
longitudinal study had the smallest sample size.  
All studies assessing an association between vitamin D and depression in the 
perinatal period employed non-probability sampling methods, with convenience and 
purposive sampling being the most common selection strategies.  Use of non-probability 
sampling is also not surprising considering the nature of the population of interest. The 
only available longitudinal study reported a retention rate across all 7 postpartum visits of 
57% (Murphy et al., 2010).  
There are a wide variety of reasons why enrollment and retention of pregnant and 
postpartum women in research is so difficult (Macklin, 2010; Wisner, Appelbaum, Uhl, 
& Goldkind, 2009; Merkatz, 1998). Partly the explanation lies with pregnant women 
themselves as there is a great deal of stigma surrounding research participation, and 
pregnant women often feel protective of themselves and their fetuses, which may make 
them reluctant to participate in research. Pregnancy and delivery also may lead women to 
   
30 
make transitions (i.e. relocate, leave their jobs, etc.) that can lead to difficulties with 
study retention. Pregnancies are also vulnerable to natural and elective mortality leading 
to study attrition and often preventing or deterring researchers from recruiting women in 
early pregnancy, thus underrepresenting them in samples. Miscarriage is the most 
common complication of early pregnancy, with 8-20% of all pregnancies less than 20 
weeks resulting in miscarriage (Wang et al., 2003). 
Barriers to enrollment and retention of pregnant women also lie within the 
scientific community. The National Institutes of Health [NIH] recognizes pregnant 
women and their fetuses as an official vulnerable population (NIH, 2001) and, as such, 
there are special research requirements and ethics that apply to them, which are important 
for their protection in research but present unique challenges to investigating this 
population.  Study enrollment is a traditionally difficult research task and adding the 
unique challenges of a pregnant population makes it particularly difficult to enroll and 
retain large samples of pregnant women.  Both study attrition and non-random sampling 
introduce bias and limit the generalizability of study findings.   
Reviewed samples noted women with high depressive symptoms and vitamin D 
deficiency tended to be younger, less likely to be married, have less education, higher 
BMI’s, lower incomes, less social support, unplanned pregnancy, and were more likely to 
smoke and use alcohol (Brandenbarg et al., 2012; Cassidy-Bushrow et al., 2012; Murphy 
et al., 2010; Nielsen et al., 2013; M. Robinson et al., 2014). Similar trends were noted in 
all studies, however not all differences were statistically significant in all studies. The 
mean age range in reviewed studies was 28.9 (5.5) to 31 (4.8) years old (Mean (SD); 
Brandenburg et al., 2012; Murphy et al., 2010), however not all studies reported mean or 
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median age for their overall samples. On average participants with depression 
(Brandenbarg et al., 2012; Cassidy-Bushrow et al. 2012) and low vitamin D levels tended 
to be younger by 1.5 years (25.8-29.9 vs. 26.9-31.4) (Murphy et al., 2010). However, two 
studies noted no significant difference in age between women with depression or vitamin 
D deficiency and non-depressed women and women with adequate vitamin D levels 
(Nielsen et al., 2013; Robinson et al., 2014). It is not surprising that studies noted slightly 
younger ages in women with depression.  Very young and older aged women may be at 
greater risk for depression. The noted finding of the association between younger aged 
women and a vitamin D deficiency is somewhat curious. Possible explanations for the 
observed younger age in the study by Murphy et al. (2010) is the high prevalence of 
vitamin D deficiency in their sample (58%) as the age of women in the deficient group 
closely approximates the mean age for the overall sample (28.1 vs. 28.9).   
The reviewed samples, although overall diverse individually, are largely 
homogenous with primary representation of White non-Hispanic/Caucasian women 
(Nielsen et al., 2013; Robinson et al., 2014) or all Black non-Hispanic/African American 
women (Cassidy-Bushrow et al., 2012). The two studies with heterogeneous samples 
(Brandenbarg et al., 2012; Murphy et al., 2010) noted ethnic disparities for both vitamin 
D deficiency and depression. Murphy et al. (2010) reported black non-Hispanic women 
were significantly more likely to be deficient than white non-Hispanic women (N=97; χ2 
= 25.3, p < .0001). Brandenbarg et al. (2012) confirmed this disparity noting a deficiency 
incidence of 60% (vs. 42% overall) in non-western women and a higher incidence of 
depression (44% vs. 23%) among this group as compared to western women in their 
sample. Samples that only represent one ethnicity control for differences in the sample as 
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a result of skin pigmentation to some degree, however limit the generalizability of their 
findings. Race/ethnicity may be a probable moderator between diabetes and depression. 
This underscores the need for diverse samples to fully understand the role of 
race/ethnicity in the association between depression and vitamin D.   
Most studies only include women receiving regular prenatal care. Women who 
are not getting regular prenatal care are significantly underrepresented in the available 
research despite their increased risk for depression (Milgrom et al., 2007). These women 
are also less likely to be screened for depression and vitamin D deficiency and may have 
undiagnosed illness; thus, even in large samples (e.g., hospital discharge data), they may 
remain hidden. This is a significant limitation of prior studies. 
The majority of the studies reviewed were conducted at one site in large urban 
medical centers or clinics in developed countries. An urban setting in a developed 
country (e.g., USA) is an ideal location for examining the link between depression and 
vitamin D deficiency, since rates of both diseases are higher in these particular areas 
(Hosseinpanah et al., 2010; Villegas et al., 2011). However, having only one site in an 
urban location limits the generalizability of study findings and makes application to rural 
and underdeveloped regions and populations difficult. While all the sampling plans 
reviewed have some weaknesses, the study by Brandenbarg et al. (2012) has a 
particularly strong sample. Those authors examined women prospectively as part of the 
Amsterdam Born Children and Their Development Cohort Study.  The major strengths of 
this sample are it’s large sample size (N=4101), ethnic diversity, a broad age range, 
population based, a variety of care providers, different insurance types, and enrolled 
women in their first trimester (Brandenbarg et al., 2012). The major weakness of this 
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sample was women self-selected to be in the study or not and authors noted that, despite 
efforts to reach non-Dutch speaking women, a bias towards more educated Dutch 
speaking women may have existed within the sample.  
Future research should include the strongest sample plans possible to facilitate the 
collection of high quality data and further the understanding of the relationship between 
depression and vitamin D in pregnancy.  Important factors to consider would be sample 
size, ethnic diversity, study location, and carefully planned inclusion/exclusion criteria. 
These factors and prior research were taken into consideration in the planning of this 
dissertation study.  
 
Designs 
Prior studies investigating the link between depression and vitamin D in 
pregnancy used a variety of designs. All of the studies reviewed that investigate the link 
between depression and vitamin D were observational in nature (Brandenbarg et al., 
2012; Cassidy-Bushrow et al., 2012; Murphy et al., 2010; Nielsen et al., 2013; M. 
Robinson et al., 2014). Study designs seen in the reviewed research regarding vitamin D 
and depression in pregnancy consist of prospective longitudinal (Murphy et al., 2010; 
Robinson et al., 2014), cross-sectional (Brandenbarg et al., 2012; Cassidy-Bushrow et al., 
2012), and case-control (Nielsen et al., 2013). Understanding the strengths and 
weaknesses of designs previously used was useful in developing the dissertation study.   
A prospective longitudinal cohort design allows researchers to investigate 
changes in characteristics across time in the sample and assess the relationship between 
risk factors on outcomes of interest. Specific to the topic at hand, this type of design 
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facilitates a better understanding of the degree to which vitamin D and depression are risk 
factors for one another and any other variables that may contribute to their relationship. 
For example, Murphy et al. (2010) noted women with vitamin D deficiency at visit 1 had 
higher depressive symptoms at time 7 as compared to women with sufficient vitamin D, 
suggesting chronic low levels of vitamin D may lead to increases in depressive symptoms 
over time. In further support of this direction of the relationship between depression and 
vitamin D Robinson et al. (2014) reported a significant association between low vitamin 
D levels in pregnancy and the development of depression postpartum. However, they did 
not measure depression in pregnancy or vitamin D levels postpartum, thus limiting their 
ability to distinguish the direction of the relationship (Robinson et al., 2014).  
Brandenbarg et al. and Cassidy-Bushrow et al. used cross-sectional designs to 
examine vitamin D and depression during pregnancy (Brandenbarg et al., 2012; Cassidy-
Bushrow et al., 2012). Participant response rates for both studies were similar and ranged 
from 31.1% (203/652) to 35.5% (4,389/12,373) of approached women. A great strength 
of cross-sectional studies is that they are able to control for a large number of covariates 
and have limited to no study attrition. Accounting for the influence of covariates gives 
information about the explanatory power of the primary variables of interest and may 
reveal important mechanisms underlying the link between depression and vitamin D 
deficiency in pregnancy. This understanding could be vital in the development of future 
interventional studies. Both studies demonstrated a significant association between low 
levels of depression and elevated depressive symptoms in pregnancy, however due to 
their design they were unable to examine direction of the association.  
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Case-control designs (Nielsen et al., 2013), like longitudinal designs, can provide 
some information on the predictive nature of vitamin D deficiency for depression (and 
vice-versa). Case-control designs provide useful information about character differences 
between the two groups. A nested case-control design is strengthened by its inclusion in a 
cohort, which typically results in a greater capacity to control for extraneous variables 
than in a non-nested design. In a nested case-control analysis of a prospective cohort 
study (Danish National Birth Cohort), Nielsen et al. (2013) compared a single vitamin D 
level drawn in pregnancy between women who filled anti-depressants in the first year 
postpartum (cases) to women who did not (controls). They excluded women with anti-
depressant use or a registered mental illness diagnosis in the year prior to delivery and 
women hospitalized for mental illness at any time (Nielsen et al., 2013). As previously 
noted they found an increased risk for anti-depressant use among women with very low 
vitamin D levels (<15nmol/L, OR 1.68) and women with very high vitamin D levels 
(≥100nmol/mL, OR 2.03; p=0.03).   
In this case, the main weakness in the case-control design was that the groups 
were created by selecting women already diagnosed with depression, which prevented the 
study from being able to address the predictive nature of depression for vitamin D and 
from establishing causality (Langer & Langer, 1994; Mautner et al., 2009). For example, 
the study by Nielsen et al. (2013) was limited in its ability to demonstrate the predictive 
nature of vitamin D (high or low) for depression. Although they attempted to exclude 
women with depression in pregnancy, vitamin D levels were not measured in the 
postpartum period. Additionally, women with depression in pregnancy may have had a 
different pathology than women with new onset depression postpartum (Altemus et al., 
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2012; Mora et al., 2009; Stowe et al., 2005) and more likely to have chronic low levels of 
vitamin D. It is also possible that some controls were depressed despite not filling 
prescriptions for anti-depressants. Finally, there is evidence that anti-depressant use 
lessens bone mass and increases the risk for fractures (Richards et al., 2007), suggesting 
that women taking anti-depressants (case group) may be predisposed to lower not higher 
levels of vitamin D further threatening the validity of the findings in this case-control 
study (Nielsen et al., 2013).  
The science concerning the relationship between vitamin D and depression in 
pregnancy is still in the developing stages with efforts focused on clearly establishing or 
refuting the existence of an association. Thus, carefully planned observational studies are 
the most appropriate design at this time. While, cross-sectional and case-control designs 
may continue to play a role, moderate to large longitudinal cohort designs are critical for 
exploring the natural history of interactions between vitamin D and depression in 
pregnancy. This type of design when feasible would be ideal for answering the question 
about a relationship between vitamin D and depression in pregnancy.  
 
Measures 
Measuring the relationship between vitamin D and depression in the most reliable 
and valid way is a critical component of the research process. Reliable measures 
consistently measure the same thing and valid measures are those that accurately measure 
the concept they were designed to measure. Therefore, a tool that is both reliable and 
valid consistently measures the concept it was created to assess. There are a wide variety 
of ways to measure both vitamin D and depression. The following assessment of most 
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commonly used measures will include a general review of their reliability and validity. 
An assessment of the usefulness of the measure for examining the association between 
vitamin D and depression in pregnancy is provided. Using the most sensitive and specific 
tool for measuring a particular phenomenon ensures the best possible understanding of 
concepts, associations, and outcomes. A review of the strengths and weaknesses of 
currently used tools for assessing the link between depression in pregnancy and vitamin 
D deficiency follows, and facilitates the identification of the best measures to be used in 
future research. 
Vitamin D. There is currently great debate surrounding screening for vitamin D 
deficiency in pregnancy. The American College of Obstetrics and Gynecology (ACOG, 
2011) and the IOM (2011) do not recommend routine screening and supplementation of 
vitamin D in pregnancy beyond what is in prenatal vitamins. However, despite 
recommendations against routine screening, this author has observed that in practice 
many prenatal providers routinely screen and treat low vitamin D levels in pregnant 
women, because of emerging evidence and growing public concern. No studies were 
found examining current provider practices for routine vitamin D screening, but authors 
in one reviewed study noted routine screening for vitamin D deficiency was standard of 
care at their institution (Cassidy-Bushrow et al., 2012).  
 All forms of vitamin D are metabolized in the same way and are useful for 
treating vitamin D deficiency disease (IOM, 2011; Jones et al., 1998). The main 
circulating form of vitamin D and the form most useful for indicating adequate levels is 
25-hydroxyvitamin D (25OHD). 25OHD is the most valid measure of vitamin D because 
it includes both what is made in the skin and ingested forms after processing through the 
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liver and prior to conversion to its active form 1,25(OH)2 vitamin D (IOM, 2011). 
25OHD is also highly stable, unlike 1,25(OH)2, and able to represent vitamin D status 
over a period of approximately 3 weeks (Wootton, 2005). 25OHD also represents the 
most cost effective way to assess for vitamin D status (IOM, 2011; Wootton, 2005; 
Zerwekh, 2008). All of the reviewed studies that assessed vitamin D levels included 
25OHD and most studies only reported total 25OHD levels. One study did report only 
25OHD3, noting 25OHD2 levels were insignificant in their sample (Nielsen, et al. 2013).   
	   There is still a great deal of variation within methods of screening, diagnostic 
values for levels of vitamin D, and time of testing. This discordance in measurement of 
vitamin D makes comparison of study findings difficult and clouds the relationship of 
vitamin D with depression and other variables. Until a consensus related to the 
measurement of vitamin D is reached, an assortment of methods will continue to be used. 
The most common methods, values, and screening times currently in use are reviewed 
below in light of recent literature and recommendations.  
Method of screening. The two main methods for obtaining 25OHD are assay kits 
and liquid chromatography–tandem mass spectrometry (LC-MS/MS). Assay kits can be 
divided into five basic categories: radioimmunoassay (RIA), enzyme-linked 
immunosorbent assay (ELISA), competitive protein binding (CPB), high-performance 
liquid chromatography (HPLC), and chemiluminescence (Zerwekh, 2008).  As a result of 
the wide variety of assays and complexities with measurement the Vitamin D External 
Quality Assessment Scheme (DEQAS) was formed and monitors inter and intra 
laboratory validity. Assay kits have improved over time and have received approval by 
the FDA for use in research, assay kits are affordable and easy to use, but are prone to 
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greater variation in results and less accurate than LC-MS/MS in differentiating between 
25OHD2 and 25OHD3 (Zerwekh, 2008).  Vitamin D is very stable and can be left at room 
temperature without degradation for up to three days (Lissner, Mason, & Posen, 1981). 
Both serum and plasma can be used for analysis of 25OHD and should be stored at -20° 
Celsius (Zerwekh, 2008). 
LC-MS/MS is considered the “gold standard” for 25OHD measurement and is 
highly accurate for measuring both 25OHD2 and 25OHD3. Disadvantages to LC-MS/MS 
are the risk of ion suppression, which can lead to the sample not yielding results, and the 
need for expensive equipment (Zerwekh, 2008). In reviewed studies the general 
procedure for processing 25OHD was as follows: whole blood was collected and 
centrifuged, serum was then aspirated off, the samples were frozen in cryotubes at -20° to 
-80° C then thawed and analyzed for 25OHD. The use of Chemiluminescence (Cassidy-
Bushrow et al., 2012), RIA (Murphy et al., 2010), ELISA (Brandenbarg et al., 2012), and 
LC-MS/MS (Nielsen et al., 2013) were all noted in the literature. Robinson et al. (2014) 
used an ELISA kit and cross-validated a subset of samples with LC-MS/MS.  
 Diagnostic values. Variations in the values used for diagnosing vitamin D 
deficiency are widespread and impede consistency in the identification of women with 
the disease for both researchers and practitioners.  Until an agreement is reached, the 
debate remains regarding which values are the most sensitive and specific for diagnosing 
vitamin D. The IOM in late 2010 defined vitamin D deficiency as 25OHD < 30 nmol/L 
(< 12 ng/ml), insufficiency as 30-50 nmol/L (12-20 ng/ml), adequate as ≥ 50 nmol/L (≥ 
20 ng/ml), and unsafe levels as > 125 nmol/L (> 50 ng/ml) (IOM, 2011). These values are 
set based primarily on the amount of vitamin D needed to maintain skeletal health as the 
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IOM deemed current data about vitamin D and other disease inconclusive (IOM, 2011). 
In the summer of 2011 the Endocrine Society defined deficiency as 25OHD < 20 ng/ml 
(50 nmol/L) and insufficiency as 21–29 ng/ml (52.5–72.5 nmol/L)(Holick et al., 2011). In 
support of this, several studies present findings that bring into question the credibility of 
the IOM ranges particularly as they relate to women (Marwaha et al., 2011) and 
pregnancy (Hollis et al., 2011; Lau et al., 2011).  
 In the reviewed literature most studies evaluated vitamin D deficiency based 
approximately on current IOM recommendations (Brandenbarg et al., 2012; Cassidy-
Bushrow et al., 2012; Nielsen et al., 2013). However, both Murphy et al. (2010) and 
Robinson et al. (2014) set their levels closer to those recommended by the Endocrine 
Society (Holick et al., 2011). Murphy et al. (2010) reported insufficiency as less than 32 
ng/ml and Robinson et al. (2014) used four cut points to create quartiles with the lowest 
quartile set at less than 47 nmol/L. The ongoing issue of acceptable parameters for 
vitamin D levels is a challenge for research in this area. Going forward, clear articulation 
of the ranges used within studies is important for the comparison of findings between and 
across studies. 
Timing of screening. Timing of vitamin D measurement varied across studies.  
Current evidence regarding changes in vitamin D across trimesters of pregnancy indicate 
that 1,25(OH)2 rises significantly from the first trimester to term, but levels of 25OHD 
remain largely unchanged (Brannon & Picciano, 2011; Marwaha et al., 2011).  Two 
studies, however, did note a slight increase of 25OHD in the third trimester (Cross et al., 
1995; Sanchez et al., 1996). With the recent advent of supplementation of pregnant 
women with vitamin D, the prescription of prenatal vitamins in the first trimester, and 
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growing popularity of vitamin D supplements, measurement of 25OHD in the first 
trimester may reflect the best baseline value.  
Assessment of measures for vitamin D. The complexity involving measurement 
of vitamin D makes the study of this disease difficult. With multiple methods and values 
for determining vitamin D deficiency researchers face problems with measure selection, 
secondary analysis, and comparison of findings. The body of literature is growing in this 
area but difficulties will still remain as researchers attempt to conduct retrospective 
analyses and compare previous study findings with current findings.  Clearly articulated 
and careful measurement of vitamin D, using the most evidenced based methods and 
values, is a critical component in understanding the relationship between vitamin D and 
depression and should be employed in future studies in this area. 
Depression and depressive symptoms. Diagnosis for depression is based on 
previously described DSM-IV criteria and requires skilled clinical assessment. It is often 
not feasible or appropriate to screen for depression by direct clinical assessment so 
researchers often screen using symptoms scales or other indicators (e.g. filling a 
prescription for an anti-depressant) for depression instead (Nielsen et al., 2013). 
Depressive symptoms and markers for depression are proxy measures for estimating the 
prevalence of depression. Symptom scales are typically used in prospective studies and 
markers are often seen in retrospective or secondary analysis designs. Accurately 
measuring depression means identifying a valid tool that is both specific and sensitive for 
a perinatal population. A measure is considered specific if it correctly identifies those 
without disease as being without disease and it is sensitive when it finds those with 
disease as having the illness of interest. While both specificity and sensitivity are 
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important in the case of depressive measures it is most critical that the tools are sensitive, 
because the result of untreated depression in the perinatal period can result in serious 
morbidity and mortality as previously described.  
The American Congress of Obstetrics and Gynecology (ACOG) currently 
recommends that all pregnant women be screened for depression at least once every 
trimester and in the postpartum period (ACOG, 2006). However, in current practice, most 
women are only screened during the postpartum period, if at all (LaRocco-Cockburn, 
Melville, Bell, & Katon, 2003). A large number of depressive symptoms scales exist and 
have been shown to be appropriate for use in pregnant and postpartum populations. The 
Center for Epidemiologic Studies Depression Scale (CES-D) (Radloff, 1977) and the 
Edinburgh Postnatal Depression Scale (EPDS) (Cox, Holden, & Sagovsky, 1987) were 
the most commonly used tools for depressive symptoms in the reviewed studies. Another 
commonly used measure for depressive symptoms is the Beck Depression Inventory 
(BDI) (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961). The BDI is not well 
represented in the studies reviewed.  Due to its high prevalence of use generally, it will be 
included in the review of measures. Of note the Postpartum Depression Screening Scale 
(PDSS) and the Patient Health Questionnaire (PHQ-9) were not included in the review 
due to their relative absence from studies concerning depression and vitamin D in 
pregnancy. An assessment of the strengths and weaknesses of the BDI, CES-D, EPDS, 
and depression markers is detailed below. 
Beck Depression Inventory. The Beck Depression Inventory (BDI) was designed 
and published in 1961 by Beck, Ward, Mendelson, Mock, and Erbaugh, revised in 1971, 
and copyrighted in 1978 (Beck, Steer, & Garbin, 1988). The BDI was designed to 
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identify depth and intensity of depression in a depressed population (Beck et al., 1988). 
According to Beck there is no formal theoretical foundation for the scale, but he did note 
that it reflects many aspects of depression theory present during the time of development 
(Beck et al., 1988; Shafer, 2006). Beck and colleagues developed the items for the scale 
based on behaviors and emotions that he noticed were unique to patients with depression 
(Shafer, 2006).  The scale is commonly used in the general population to screen for 
depression or depressive symptoms (Beck et al., 1988; Kendall, Hollon, Beck, Hammen, 
& Ingram, 1987; Shafer, 2006). The BDI was originally designed to be administered by 
researchers, but is now often self-administered (Beck et al., 1988; Kendall et al., 1987; 
Shafer, 2006).  
There are two major forms for the BDI: a long form and a short form  (Beck et al., 
1988). The short form consists of 13 items. It was noted to have a strong correlation with 
the long form of the BDI (α =0.96) in one large study by Beck, Rial, & Rickels (1974). 
The long form of the scale has three versions. The original 1961 version was revised for 
the DSM-III diagnostic criteria in 1971 (BDI-IA) and copyrighted in 1978 (Beck et al., 
1988). This same BDI was again revised to reflect DSM-IV criteria in 1996 as the BDI-II 
(Beck, Steer, Ball, & Ranieri, 1996). The BDI-II is comprised of 21 individual items that 
examine both psychological and physical depressive symptoms (Beck et al., 1996). The 
BDI-II also asks about depressive symptoms over the last two weeks instead of the past 
week (Beck et al., 1996) as in previous versions. Each of the items represents a particular 
aspect of depressive symptomatology and has four potential options ranging from zero to 
three with increasing numbers corresponding to increasing depressive symptomatology 
(Beck et al., 1988; Kendall et al., 1987; Shafer, 2006). To calculate a total score, 
   
44 
responses for each of the items are tallied together, total scores range from 0 to 63 (Beck 
et al., 1988; Kendall et al., 1987; Shafer, 2006).  
A wide variety of optimal cut-off values for the BDI have been reported.  
although not diagnostic, in an average population sample, a cut-off score of 21 for the 
BDI tends to indicate depression.  For a sample with diagnosed depression a BDI score of 
greater than 17 indicates current intensity of moderate to severe depression (Beck et al., 
1988; Kendall et al., 1987; Shafer, 2006).  Typically the cut-off of 21 is used in a 
perinatal population as well; however, it has been suggested that lower cut-off scores may 
be more accurate for this population (Chaudron et al., 2010). The BDI can classify the 
intensity of depression into subcategories, but it does not have any formal subscales 
(Beck et al., 1988; Kendall et al., 1987; Shafer, 2006).  
The BDI is both a valid and reliable scale with over 1,000 studies representing its 
use (Beck et al., 1988; Kendall et al., 1987; Shafer, 2006). Beck et al. (1988) analyzed 25 
studies looking at internal consistency for the BDI. They found that for groups with 
mental illness the mean coefficient alpha was 0.86, and for samples without psychiatric 
disease the mean alpha was 0.81 (Beck et al., 1988). The BDI was found to be 
moderately correlated with the CES-D in a sample of adolescent mothers (r = 0.58) 
(Wilcox, Field, Prodromidis, & Scafidi, 1998), although it is surprising that a greater 
correlation was not found. The BDI and the BDI-II have been shown to be correlated 
with the EPDS (0.68-0.82) in postpartum populations (Teissedre & Chabrol, 2004; Lee, 
Yip, Chiu, Leung, & Chung, 2001) and is noted to have moderate to high (0.58-0.79) 
concurrent validity with most depression scales (Richter, Werner, Heerlein, Kraus, & 
Sauer, 1998). 
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Consistent with higher rates of depression, women tend to have higher scores on 
the BDI than men (Beck et al., 1988). For the population of pregnant and postpartum 
women, both the BDI and the BDI-II have been shown to be moderately sensitive (BDI 
82%) (BDI-II 57-74%) and highly specific (BDI 89%) (BDI-II 83-97%) (Beck & Gable, 
2001; Chaudron et al., 2010; Lee et al., 2001; Su et al., 2007). In general the literature 
indicates that the BDI and BDI-II tend to perform well in a perinatal population, but may 
not be as sensitive or as acceptable as other scales in this population (specifically, the 
EPDS) (Gjerdingen & Yawn, 2007; Hewitt 2009; Lee et al., 2001; Su et al., 2007; Wilcox 
et al., 1998). 
 Harrington and Greene-Harrington (2007) noted that when the BDI is used with 
other depressive screens it allows for a more dynamic assessment of depression because 
the BDI indicates both presence and severity of depression. Strengths of the BDI and 
BDI-II are its ability to measure severity of depression and its broad use in a variety of 
populations.  Additional strengths of the BDI-II include its close approximation to DSM-
IV criteria.  Weaknesses of the BDI include a lower sensitivity as compared to other 
measures in a perinatal population and items that include some symptoms that may be a 
normal part of the perinatal period. 
Center for Epidemiologic Studies-Depression Scale.  The Center for 
Epidemiologic Studies Depression Scale (CES-D) was developed and refined by Lenore 
Sawyer Radloff (1977) at the Center for Epidemiologic Studies within the National 
Institutes for Mental Health (Eaton, Muntaner, Smith, Tien & Ybarra, 2004). Radloff 
(1977) developed the CES-D to screen for depression among the general public (Shaffer, 
2006). The theoretical underpinnings and components of the scale were derived from 
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popular depression screens and theories existing at the time of its development (Eaton et 
al., 2004; Radloff, 1977; Shaffer, 2006).  
Some of the most prominent scales Radloff employed to develop the CES-D were 
the Beck Depression Inventory (BDI), the Raskin Depression Rating Scale, the 
Minnesota Multiphasic Personality Inventory (MMPI), and the Zung Self-Rating 
Depression Scale (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961; Radloff, 1977; 
Eaton et al., 2004; Raskin, Schulterbrandt, Reatig, & McKeon, 1969). The CES-D was 
developed originally to be administered by interviewers, but has since evolved to be self-
administered in a variety of formats (i.e., paper-and-pencil, phone, electronic, etc.) (Eaton 
et al., 2004). The CES-D is now one of the most widely used depression screens in the 
U.S. and has been tested among many different settings, ages, races, and languages 
(Eaton et al., 2004; Shaffer, 2006).   
The 20-item CES-D primarily measures emotional and physical attributes of 
depression (Eaton et al., 2004; Radloff, 1977; Shaffer, 2006). It evaluates for depressed 
mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, 
psychomotor retardation, loss of appetite, and sleep disturbance (Eaton et al., 2004; 
Radloff, 1977; Shaffer, 2006). For each of the 20 items there is an ordinal response scale 
ranging from zero (“rarely or none of the time”) to three (“most or all of the time”), 
representing the number of times in the past week the person taking the scale has felt or 
experienced what is described in the item (Radloff, 1977).  
The items are scored by tallying the total number on each of the items, except 
items 4, 8, 12, and 16 which are reverse scored because they are positive affect items; the 
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range of possible total scores is 0 to 60 (Radloff, 1977). One drawback to the 
combination of both positive and negative items is that it can create falsely elevated CES-
D scores as a result of misunderstanding or item confusion on the part of the respondent 
or the researcher may miscalculate the score (Shafer, 2006). Although this is a potential 
problem for any scale designed in this way, the CES-D has been noted to be particularly 
problematic, possibly due to the positively worded items being dispersed throughout the 
scale as opposed to grouped together.  
Total CES-D scores greater than 16 have been positively correlated with 
diagnosed depression (Radloff, 1977) although the CES-D is not diagnostic for 
depression.  It was primarily designed to measure depressive symptomatology and 
depressed mood (Eaton et al., 2004; Radloff, 1977). Radloff (1977) originally reported 
that scores of 16 or higher were useful for distinguishing a psychiatric population, many 
with clinical depression, from the general population. Since her original work there has 
been much discussion on the ideal cut off score, with some suggesting that a cut off of 16 
is too low and leads to high false positive rates (Zich, Attkisson, & Greenfield, 1990). 
However, the value of 16 or higher remains the established standard for use in most 
populations (Thomas, Jones, Scarinci, Mehan, & Brantley, 2001).  
Reliability of the CES-D is evident in many populations with a general test-retest 
reliability of about 0.4 to 0.7 and Cronbach’s alpha coefficients of 0.85 to 0.90 (Radloff, 
1997; Eaton et al., 2004). Christian, Franco, Iams, Sheridan, and Glaser (2009) noted the 
CES-D is an appropriate measure in a sample of low-income pregnant women. The CES-
D has been shown to be moderately correlated with the EPDS (0.63 to 0.77) (Anderson, 
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2010; Logsdon & Myers, 2010; Logsdon, Usui, & Nering, 2009) and the BDI as noted 
above.  
The CES-D was used in two of the reviewed studies regarding the link between 
vitamin D and depression in pregnancy (Brandenbarg et al., 2012; Cassidy-Bushrow et 
al., 2012).  It seemed to be a valid measure of depressive symptomatology and a useful 
tool for better understanding the relationship of interest. Both studies reported using a 
cut-off score of 16 to distinguish between women with high depressive symptoms and 
those with low depressive symptoms and reported a high reliability coefficient (α = 0.90) 
(Brandenbarg et al., 2012; Cassidy-Bushrow et al., 2012). Specificity and sensitivity have 
been reported as high (0.92-0.97) and low (0.43-0.60) in a perinatal population (Campbell 
& Cohn, 1991; Gaynes et al., 2005). And in a study of adolescent mothers (Wilcox et al., 
1998) the CES-D was found to be more acceptable by participants over the BDI. The 
CES-D is a reliable and valid scale that has been widely used in many populations.  
Although it is acceptable for use in a perinatal population it may not be as sensitive as 
other screens in identifying pregnant or postpartum women with depression. 
The Edinburgh Postnatal Depression Scale. The Edinburgh Postnatal 
Depression Scale (EPDS) was developed by Cox, Holden, and Sagovsky and published in 
1987. They designed the scale because they observed there was no valid tool to screen for 
postpartum depression in the general community (Cox et al., 1987). They built the items 
in the EPDS scale through close examination of the Depression and Anxiety Scale 
(Snaith et al., 1978), the Hospital and Anxiety Scale (Zigmond & Snaith, 1983), and the 
Anxiety and Depression Scale (Bedford & Foulds, 1978).  Cox et al. did not note a 
specific theoretical basis for their scale development beyond their review of scales and 
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their own research in which they discovered a high prevalence of untreated depression in 
postpartum women (Cox et al., 1987).  
Initially the scale had 21 items derived from the reviewed existing scales and 
from the researchers’ own ideas surrounding traits of postpartum depression (Cox et al., 
1987). They piloted items and after an extensive factor analysis, identified 10 items to be 
most specific and valid for measuring postpartum depression (Cox et al., 1987). EPDS 
items do not include physical symptoms that may be considered physiologically normal 
during the perinatal period, such as those in the CES-D (e.g., “my sleep was restless”). 
Factor analysis of the scale reveals the most parsimonious model is the two factor model 
with depression and anxiety as the two factors (Phillips, Charles, Sharpe, & Matthey, 
2009). Interestingly, depression loads on seven of the 10 items and anxiety loads on the 
other three items creating a small anxiety subscale of the EPDS, the EPDS-3A (Matthey, 
2008).  Evidence exists to support its use as a measure for anxiety in both pregnant and 
postpartum populations (Matthey, Fisher, & Rowe, 2013). 
The EPDS is usually self-administered or given orally by a general practitioner 
and takes approximately 5 minutes to complete (Cox et al., 1987). For each of the 10 
items there are four possible responses on an ordinal response scale ranging from zero to 
three and correlate with the intensity of depressive symptomatology (Cox et al., 1987). 
The total score is calculated by tallying each of the items, with items 3, 5, 6, 7, 8, 9, and 
10 being reverse scored (Cox et al., 1987). The total possible score for the EPDS ranges 
from 0 to 30 with cut-off scores listed in the literature anywhere from 9 to 15 and/or 
positive suicidal ideation correlating with depression (Cox et al., 1987; Murray & 
Carothers, 1990; Sit & Wisner, 2009). There is great debate surrounding the appropriate 
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cut-off values to use. A cut off value of 10.5 captures approximately 90% of women with 
depression, but with a high false positive rate (Cox et al., 1987; Murray & Carothers, 
1990).  
Most research on the EPDS notes a cut-off of 13, which yields a broad range of 
reported sensitivity (65-100%) and specificity (77%-92%) (Cox et al., 1987; Gaynes et 
al., 2005; Su et al., 2007; Lee et al., 2001). In a large meta-analysis examining several 
different measures for perinatal depression, the EPDS was found to have higher 
sensitivity for detecting major depression than other scales (Hewitt et al., 2009). When 
used, the EPDS is generally well accepted by practitioners and participants (Hewitt et al., 
2009). The EPDS was originally developed to be used to screen for depression in the 
postpartum period (up to eight weeks postpartum), but has also been tested and validated 
among all periods of pregnancy and in non-pregnant populations (Cox, Chapman, 
Murray, and Jones, 1996; Lee et al., 2001; Murray & Carothers, 1990; Su et al., 2007; 
Yonkers, Smith, Gotman, & Belanger, 2009). The EPDS has demonstrated good 
convergent validity and has been shown to be moderately correlated with both the BDI 
and CES-D. 
The EPDS has several advantages. It has higher sensitivity than other scales in 
identifying major depression in a pregnant population (Gaynes et al., 2005).  It is brief 
and designed specifically for the perinatal period (Cox et al., 1987), and highly 
acceptable to women when surveyed and is widely used to screen for perinatal depression 
(Chaudron et al., 2010; Gjerdingen & Yawn, 2007; Hewitt et al., 2009). Noted 
disadvantages of the EPDS are that it measures depressive symptoms as a state.  This can 
lead to variation in the scores over time.  Without repeat testing it is difficult to know if 
   
51 
the scores are fully representative of the emotional state of the participant over time (Cox 
et al., 1987; Murray & Carothers, 1990). The EPDS more accurately identifies major 
depression than both major and minor depression as compared to other commonly used 
depressive measures (Hewitt et al., 2009).   
The EPDS was used in reviewed literature examining vitamin D and depression in 
the perinatal period (Murphy et al., 2010; Robinson et al., 2014). Murphy et al. (2010) 
used a cut-off score of greater than 9 to include all women with possible depression, both 
major and minor.  They did not report a reliability coefficient for their study. Robinson et 
al. (2014) used a modified six questions version of the EPDS to assess for “anxiety, 
sadness, mood fluctuation, tearfulness, appetite changes, and sleep disturbances not 
related to caring for the baby.” They did not specifically indicate, which items they 
included. They summed the six items on the same four-point scale as the original EPDS 
to create a “blues” score and used a cut-off score of 6 or higher to indicate elevated 
depression. They also did not report a reliability coefficient for their study (Robinson et 
al., 2014).  
Markers for depression. Another method to assess for existing depression is to 
use a variety of markers for depression. For example, markers for depression in the 
perinatal period may include abstraction of a diagnosis from medical records (Schneid-
Kofman et al., 2007), ICD-9 codes for depression (Bansil et al., 2010; Kozhimannil et al., 
2009), or filling a prescription for an anti-depressant medication (Nielsen et al., 2013). 
Depression markers such as these may be less reliable and less valid than direct 
measurement of depression. They may be vulnerable to variation in method, criteria, 
diagnostician or coder, and interpretation (e.g., anti-depressant medications can be taken 
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for reasons other than depression). These vulnerabilities can be a threat to the internal 
validity of the study.  However, where it is not possible to use direct measures (e.g., 
secondary analysis) efforts can be made to minimize these threats. Some ways to 
minimize threats to internal validity when using markers are to use more than one marker 
for depression, confirm ICD-9 codes with medical records, and check for validity by 
examining diagnostic and coding processes.  
When using markers for depression it should also be taken into consideration that 
depression is classically under diagnosed and therefore actual prevalence in the sampled 
population may be much higher than indicated by markers (Rasmussen-Torvik, & 
Harlow, 2010).  The study by Nielsen et al. (2013) used filling a prescription in the first 
year after giving birth as inclusion for their case group. Although antidepressant use as a 
marker for depression may be specific, most women taking antidepressants are depressed. 
It’s sensitivity as a marker has been reported at approximately 50% meaning many 
depressed women are not on antidepressants (Thielen et al., 2009).  
Assessment of depression and depressive symptom measures. Accurately 
measuring depression is a critical part of developing an understanding of the link between 
depression and vitamin D. Use of a depressive symptom scale to screen for depression is 
superior to using markers for depression. Depressive symptom scales are typically higher 
level data, provide direct assessment of symptoms in a controlled and standardized 
manner, and provide dynamic information about depression beyond just its presence or 
absence.  
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The BDI, CES-D, and EPDS are all widely used and valid in a perinatal 
population. Of these scales, the EPDS appears to be the most widely used to measure 
perinatal depression and has the highest sensitivity of the three in a perinatal population. 
The EPDS also has the additional value of a small anxiety subscale. Most sources agree 
that more research with large diverse samples is needed before a gold standard for 
depressive symptom measurement in pregnancy can be established (Gjerdingen & Yawn, 
2007). 
 
Analysis 
Statistical analysis is a test of the study hypothesis (Trochim, 2001) through an 
examination of collected data. Analysis methods are based on sample, design, measures, 
and data collected. The reviewed studies used a variety of univariate, bivariate and 
multivariate statistical analyses including the following: descriptive statistics, chi-square, 
student’s t-test, correlational methods (e.g., point-biserial correlations), analysis of 
variance, and multivariate linear and logistic regressions. Descriptive statistics were used 
to describe samples and chi-square or t-test to examine differences between groups; for 
example, depressed and non-depressed	  or	  deficient	  and	  sufficient	  women	  (Brandenbarg	  et	  al.,	  
2012;	  Cassidy-­‐Bushrow	  et	  al.,	  2012;	  Murphy	  et	  al.,	  2010;	  Nielsen	  et	  al.,	  2013;	  Robinson	  et	  al.,	  
2014).	  	  
Regressions, especially multivariate hierarchical models, allow researchers to test 
multiple hypotheses and adjust for the influence of other variables on the association. 
Both regressions and correlations allow for a two-tailed assessment looking for both 
positive and negative associations. Examining both positive and negative aspects of 
associations between vitamin D, depressive symptoms, and significant covariates can be 
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useful as we develop a better understanding of the relationship between vitamin D and 
depression. Primary issues to consider when using regressions are the level of data, 
number of cases (sample size), inter-correlations between variables, and multicollinearity. 
Level of statistical significance used is also an important component in evaluating 
analysis and findings. Three of the reviewed studies used logistic regression 
dichotomizing women as depressed vs. non-depressed or having insufficient vs. sufficient 
vitamin D levels (Brandenbarg et al., 2012; Cassidy-Bushrow et al., 2012; Nielsen et al., 
2013). Nielsen et al. (2013) added a fractional polynomial of the degree 3 citing the need 
for greater flexibility in light of debate around appropriate vitamin D levels.  
A generalized linear mixed models (GLMM) approach can be applied to a 
longitudinal design and allows for dependent repeated measures (within subjects) 
analysis. The GLMM also allows for the “control” of covariates. The GLMM gives 
individual participant level data (intercept and slope), which can be used to predict 
participant level patterns. This may be a useful tool for dealing with missing or 
incomplete data. A GLMM is considered mixed because it includes both "random" and 
"fixed" factors. The GLMM addresses questions about the longitudinal relationship 
between the vitamin D and depression in pregnancy. Two studies reported using general 
linear models (Murphy et al., 2010; Robinson et al., 2014) to analyze their data. All 
reviewed studies use a statistical significance level less than 0.05. This level of 
significance is appropriate for research attempting to establish a relationship between 
GDM and PD. 
Many of the reviewed studies analyzed their data using logistic or linear 
regression analyses.  It was noted in review that vitamin D levels and depression scores 
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were not normally distributed and required transformation or grouping. Several studies 
opted to group their findings into depressed or not depressed and/or adequate vs. 
inadequate vitamin D levels. Many of the studies attempted to control for known 
covariates. Many of the studies failed to give a complete report of statistical findings 
including: a clear indication of the level of measurement used for analysis, inter-
correlation values, report of R-squared change, and an evaluation of residuals.  
 
Synthesis of Methodological Knowledge 
A review of research methods currently used to examine the association between 
vitamin D and depression in pregnancy was conducted. Several issues emerged as 
important to consider in planning future studies.  Despite potential challenges, efforts to 
enroll and retain a moderate to large ethnically diverse groups of women across the 
perinatal period is important. Ideally, samples selected should include women who are 
not regularly receiving prenatal care in order to obtain a true representation of the 
pregnant population. Lastly, when sampling and enrolling within this vulnerable 
population, protections should be in place to prevent violations of research ethics. 
An assessment of designs demonstrated that a prospective longitudinal cohort 
design may be highly useful for answering questions about the link between vitamin D 
and depression in pregnancy, because it can assess concurrent risk and provide a natural 
history of the illnesses. Regarding designs generally, knowledge regarding the association 
between vitamin D and depression in pregnancy is in the developmental stages where 
observational designs tend to be more appropriate than interventional ones. As this 
   
56 
understanding develops, interventional studies will be critical in the translation of 
knowledge to treatment. 
A critical evaluation of currently used measures for vitamin D and depression in 
pregnancy revealed that direct measurement of the illness (e.g., depression scales) is 
superior to indirect quantifying by using markers for illness (e.g., filling an antidepressant 
prescription). For measuring vitamin D either IOM or Endocrinology recommendations 
can be used, although emerging evidence makes a strong case for the second. For method 
of measurement first trimester measurement of 25OHD using mass spectrometry appears 
that the most accurate. A review of direct measures for depression in pregnancy suggests 
that measuring depressive symptoms using a validated screen is more feasible than 
clinical evaluation and more sensitive than using proxy markers for depression. There is 
no consensus on the ideal measure for depression in pregnancy but use of the EPDS with 
screening in each trimester holds high promise for examining the relationship between 
depression and vitamin D in pregnancy. Statistical analysis should allow for the detection 
of both negative and positive associations; a thorough report of statistical findings should 
be included; and both non-statistically significant observed trends as well as statistical 
significance of study findings should be considered.  
 
Theoretical Framework 
Methods are important building blocks in the development of future research. 
Theories and concepts can provide a framework upon which to build our understanding 
of the phenomenon of interest. None of the studies reviewed for this project included a 
   
57 
clear theoretical model beyond descriptions of biological mechanisms (Brandenbarg et 
al., 2012; Cassidy-Bushrow et al., 2012; Murphy et al., 2010; Nielsen et al., 2013; 
Robinson et al., 2014).  However, a broader review found that concepts for the theory of 
maternal role attainment have been used to guide the examination of depressed mood and 
other pathology (e.g., diabetes) in the perinatal period (Chazotte et al., 1995).  
Additionally, many studies reviewed noted that life stress and anxiety might have 
a role in the association between depression and vitamin D (Berk et al., 2007; Berk et al., 
2013; Murphy et al., 2010). The concept of life stress on disease pathology and coping 
fits well with the transactional model of stress and coping, which emphasizes the 
importance of appraisal or perception of the stressor(s) (Lazarus & Folkman, 1984).  
Stress and coping in non-pregnant women with depression have been examined through 
the lens of the transactional model and the concepts of the model have been applied in 
several diseases processes and study designs (Rao, 2009).  An overview of these theories 
and their usefulness is detailed below. 
 
Maternal Role Attainment  
Maternal role attainment theory concepts have been applied in research examining 
the link between gestational diabetes mellitus and postpartum depression (Chazotte et al., 
1995). Maternal role attainment is the theory of maternal identity described by Rubin and 
Mercer (Rubin 1967; Mercer, 1981).  The original model by Rubin is the adaptation of 
the feminine identity to describe a maternal identity by moving through four maternal 
tasks within the self-system (ideal self, body image, self image; Rubin, 1967; 1984) (see 
Figure 2). Rubin based her theory on Theodore Sarbin’s and George Mead’s theories 
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about role attainment (Sarbin, 1954; Mead, 1934). Rubin’s own ideas developed from her 
initial dissertation work to the publishing of models of the theory (Rubin, 1967). 
Continued work yielded a more parsimonious version of the theory (1976) that was 
eventually documented in detail in Maternal Identity and the Maternal Experience 
(1984).  Rubin’s (1967) model was later adapted by Mercer (1981) to look at the role of 
maternal role attainment in the first year of motherhood and the processes that women 
move through with their infant during that time.  
Maternal role attainment as described by Rubin is distinctive because of its multi-
relational linkages, specific tasks for pregnancy, and focus on the maternal identity. The 
concept of maternal identity is the adaptation of self as a mother and all the desired 
characteristics, emotions, and behaviors that accompany motherhood (Rubin, 1984). This 
process of incorporating a view of self as mother is described as three images of self and 
four maternal tasks. Replication is part of the change in self-perception and occurs when 
the woman observes behaviors that correlate with her belief of motherhood and copies 
them within herself (e.g., wearing maternity clothes prior to needing them). This “taking-
on” or copying of others does not mean that these characteristics or behaviors have been 
incorporated into the woman’s self, but she is feeling them out to see if they will 
eventually mesh with her (1984). It is not only critical that the woman achieve “a 
functional equilibrium of self in a dynamic system” to obtain maternal identity, but she 
must also move through a series of four maternal tasks: seeking safe passage, acceptance 
by others, binding-in, giving of oneself (Rubin, 1984 p.52). It is these tasks and the focus 
on maternal identity that make this theory unique.  
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Also the importance of binding-in or bonding between mother and her newborn 
has been affirmed in the literature (Klaus & Kennell, 1998). Examples of the research 
topics that have resulted from Rubin’s theory include maternal and infant bonding (Klaus 
& Kennell, 1998), postpartum depression (Beck, 1995), and teen or high-risk pregnancies 
(Mercer, 1980).  Mercer and others have used the concepts of role, self-identity, and 
attachment from Rubin’s theory to explore aspects of vulnerable pregnant populations 
and possible interventions to improve their outcomes (Mercer, 1981; Beck, 1995; Ament, 
1990).  Maternal role attainment theory predicts the outcome of emotional stability or 
instability based on the completion of the maternal tasks and the integrity of the self-
system (Rubin, 1984).  
 
Figure 2. Model of maternal role attainment 
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Transactional Model of Stress and Coping  
The transactional model of stress and coping was developed by Lazarus and 
Folkman (1984) to describe stress as both internal and external events that have negative 
effects (e.g., vitamin D deficiency) on the person experiencing them and are ameliorated 
or reduced by the person’s innate ability and available resources to help them cope (see 
Figure 3). The transactional model of stress and coping begins with a stressful stimulus, 
which is then processed by the individual through primary and secondary appraisal 
(Lazarus & Folkman, 1984). Primary appraisal is one’s interpretation of a stressor as a 
threat, and secondary appraisal involves analyzing one’s ability to control the stressor 
(Lazarus & Folkman, 1984).  Glanz et al. (2002) further describes stressors as “demands 
made by the internal or external environment that upset balance or hormones…” (p. 211). 
There are both psychosocial stressors (e.g. poor social support) and biological stressors 
(e.g. vitamin D deficiency), which are “demands” that can be categorized as stressors in 
pregnant women.  
The transactional model is linear, general in nature, and describes a coping 
process (Glanz et al., 2002). Coping with stress is described by Lazarus (1993) as being 
viewed as style or process. Style refers to the person’s personality or personal 
characteristics and process refers to steps and behaviors or actions to improve coping. 
Coping as a style is hierarchical, and derived from psycho-developmental stages and 
traits based in popular psychology (Lazarus, 1993). Coping as a process is what Lazarus 
employs and describes as “something that changes overtime in accordance with the 
situational context in which it occurs” (Lazarus, 1993). He proposes that coping as a 
process is examined separately from outcomes, so that thoughts and behaviors are not 
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biased by the outcome of their use. According to Lazarus (1993), coping must always be 
examined within the context within which it is occurring. Lazarus says it is very 
important to assess “what the person is thinking and doing” both in relation to themselves 
and others (intra- and inter-personal dynamics). Continued use or adoption and 
consolidation of coping methods should also be investigated (Lazarus, 1993). It is also 
important to analyze both “problem-focused” and “emotional” coping, particularly in the 
context of relationships.  
The concept of emotional coping as a response to stress is most relevant for 
pregnant women as they cope with the stress of their pregnancy. The feelings and 
emotions they experience will drive their ability to cope well and successfully reduce 
their stress. This model has been used to evaluate the stress that women experience in 
pregnancy and how their ability to cope affects their health and the health of their 
developing infant (Huizink, Robles de Medina, Mulder, Visser & Buitelaar, 2002). The 
concepts of stress and outcomes as mediated by coping in the transactional model are 
useful for developing a framework for better understanding the association between 
vitamin D and depression in pregnancy.  
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Synthesis of Conceptual and Theoretical Knowledge 
The transactional model and the theory of maternal role attainment have 
commonalities which allow them to both describe, in part, an association between 
vitamin D deficiency and depression in pregnancy. A review of the shared strengths and 
relevant weaknesses of the two models for describing the link between vitamin D and 
depression in pregnancy lays a foundation for designing a framework that incorporates 
these strengths and addresses significant gaps. The transactional model and the model for 
maternal role attainment have shared ground in personal perception of the problem 
(appraisal and self-system), addressing stressful stimuli (coping with stress and moving 
through maternal tasks), and specific outcomes (outcomes of coping and maternal 
identity). Also both theories describe a process, have a goal of personal well-being, depict 
the individual as vulnerable to stress, and include involvement with personal 
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characteristics (Glanz et al., 2002; Rubin, 1984). They are both influenced by personal 
attributes. In the transactional model the appraisal process is heavily influenced by 
personal attributes, and the self-system in the maternal role attainment theory (Glanz et 
al., 2002; Rubin, 1984). The models stem from behaviorism ideology with both symbolic 
interactionism and social cognitive theory originating from a behaviorist background and 
both theories being mediated by behaviors (coping and maternal tasks) (Graham, 2010).  
Finally, they both propose to predict outcomes from stressors based on behaviors. 
 
Proposed Model for Dissertation Study 
The model designed by Rubin has high relevance for pregnant women, but	  lacks	  
simple	  usefulness	  for	  designing	  a	  study	  to	  assess	  the	  link	  between	  depression	  and	  low	  vitamin	  D	  
in	  pregnancy.	  The	  transactional	  model	  lacks	  specific	  relevance	  for	  pregnant	  women,	  but	  poses	  a	  
clear	  framework	  for	  understanding	  stress,	  response,	  and	  outcome.	  Since,	  neither	  of	  the	  models	  
found	  in	  the	  literature	  pertaining	  to	  the	  relationship	  between	  vitamin	  D	  deficiency	  and	  
depression	  in	  pregnancy	  provide	  a	  sufficient	  framework	  for	  explaining	  the	  association,	  a	  new	  
model	  is	  hereafter	  described.	  	  
The proposed framework (see Figure 4) is derived from the transactional model 
where vitamin D deficiency is the primary stressor and depression is the possible 
outcome. The framework is further modified by the incorporation of the concept of 
maternal identity as a possible moderator on depression and inflammation as the 
mediator, a form of biological “coping”, on the association between vitamin D and 
depression in pregnancy. Moderators and mediators are distinct pieces of the theoretical 
framework. The difference between these two concepts has been stated by Barron and 
Kenny (1986), “Whereas moderator variables specify when certain effects will hold, 
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mediators speak to how or why such effects occur” (p.1176). Moderators act 
independently on the outcome of interest and mediators explain the interaction between 
the two variables (Barron & Kenny, 1998). It is important to note is that the concepts 
have been placed within in the framework as mediators or moderators, but since the 
association between vitamin D and depression is still under investigation these roles are 
only hypothetical for this proposed framework. The proposed model presents a broad 
view of the hypothesized relationship between vitamin D deficiency and depression in 
pregnancy. 
Figure 4. Theoretical Framework for depression and vitamin D in pregnancy 
 
Pregnant state. The pregnant state is the condition in which the woman finds 
herself immediately after conception until completion of delivery. This state is marked by 
dramatic physiological changes within the maternal environment in order to accept and 
sustain the developing fetus. These changes have an effect on the entire woman and 
constitute an increased demand on all body systems. For this reason, the state of 
pregnancy can be considered a stressful stimulus or stressor since it places unique 
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demands and strains on a woman’s body that have been identified as both 
psychologically and physiologically stressful (Williams, 2003).  
The changes that a woman undergoes during pregnancy are too numerous to be 
reviewed here. There are specific changes, however, that have particular relevance in 
understanding the link between depression and vitamin D. In pregnancy many women 
normally display changes that are often thought to be signs of depression in the non-
pregnant female. These include changes in sleep, increased fatigue, changes in appetite, 
reduced sex drive, cognitive changes, and physical symptoms such as back pain. Pregnant 
women experience serious sleep disturbances with increases in sleep in the first trimester, 
decreases in their sleep in the third trimester, more frequent night awakenings, and 
reductions in deep periods of sleep throughout the pregnancy period (Gabbe et al., 2007). 
Often these changes in sleep coupled with increasing metabolic demands, hormonal 
changes, and a rising cardiovascular demand will make women feel fatigued (Gabbe et 
al., 2007). 
Many women also experience changes in appetite during pregnancy with a 
possible decrease in the first trimester related to feelings of nausea and increases in the 
second and third trimesters (Gabbe et al., 2007). Many women experience reductions in 
sex drive secondary to hormonal changes, physical discomforts, or body image concerns. 
Cognitive changes in pregnancy have been reported by women and noted by researchers 
with probable explanations relating to sleep disturbances, hormonal changes, and 
preoccupation with fetal well-being and delivery (Rendell & Henry, 2008). Women also 
have physiologic alterations in metabolism, and all pregnant women experience some 
glucose intolerance (Gabbe et al., 2007). Pregnant women tend to have a more dramatic 
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response to both fasting and feeding that has been linked to human placental lactogen, 
estrogen, cortisol, progesterone, and human placental growth hormone (Gabbe et al., 
2007).  It is generally accepted that overall levels of vitamin D in pregnant women tend 
to be lower than in the general population (Holmes et al., 2009). Most studies also note 
25OHD tends to be stable across pregnancy, but that the active form of vitamin D 
(1,25OHD) is dramatically higher in pregnant women and rises over the course of 
pregnancy (Brannon & Picciano, 2011; Marwaha et al., 2011). These normal alterations 
in the maternal physiology as a result of the pregnant state are an important to consider 
when investigating the association between vitamin D and depression within the context 
of pregnancy.  
The relationship between vitamin D and depression. Vitamin D acts as a 
neurosteroid with direct affects on brain development and function (Eyles et al., 2009; 
Eyles, Smith, Kinobe, Hewison, & McGrath, 2005; Harms, Burne, Eyles, & McGrath, 
2011; Kesby, Eyles, Burne, & McGrath, 2011). Both vitamin D receptors and 1α-
hydroxylase have been found in the brain suggesting low levels of vitamin D may be 
linked to neuropathology (Eyles et al., 2005).  There is evidence in animal models that 
developmental vitamin D deficiency can lead to brain abnormalities that closely mimic 
those observed in individuals with schizophrenia (e.g. enlarged ventricles) (Eyles et al., 
2009) demonstrating that vitamin D may be critical for normal cognitive development 
and function.  
Typically, in theoretical frameworks, depression is categorized as an outcome that 
occurs when the person is unable to cope effectively and depressive symptoms are the 
outcome variable in this study. In light of the strong biological role vitamin D plays in 
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immune regulation, neurologic function, and reproductive systems vitamin D is 
hypothesized to be the independent variable leading to an outcome of depression in the 
theoretical framework for this study. The hypothesized direction of the relationship 
between low levels of vitamin D and increased depressive symptoms is that low vitamin 
D may be predictive of depression.  As previously discussed two studies found lower 
vitamin D levels in early pregnancy were associated with depression later in pregnancy or 
postpartum (Cassidy-Bushrow et al., 2012; M. Robinson et al., 2014), however these 
studies were limited by designs and were unable to demonstrate causality.  
Therefore, it is entirely possible that the relationship between vitamin D and 
depression is bidirectional. However, as a result of pathological development it is often 
difficult to discern cause-effect timing of depression and vitamin D deficiency. For 
example vitamin D deficiency may not be noted until the initial prenatal visit at 10 weeks 
gestational age.  However, the vitamin D levels of the woman prior to pregnancy are 
often unknown. This same issue with timing and progressive development is also true 
with depression. Further research is needed to validate the association between vitamin D 
and depression in pregnancy and investigate its direction. 
In light of the complexities of potential associations between vitamin D and 
depression in pregnancy a conceptual model describing possible relationships is included 
(see Figure 5).  A greater understanding of inflammation as the underlying biological 
mechanisms may begin to elucidate the nature of the direction of the relationship between 
depression and vitamin D in pregnancy.  
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Figure 5. Conceptual model of possible relationships between vitamin D (Vit D) and 
depressive symptoms (DepSx).	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Inflammation. The mechanism underlying the hypothesized association between 
depression and low vitamin D levels may be at least in part be mediated by inflammation. 
There is sufficient evidence to suggest that inflammation may be an important mediator 
in the pathophysiology of depression (Leonard & Maes, 2012; Maes et al., 2011).  Recent 
literature demonstrates increased oxidative and nitrosative stress and immune dysfunction 
in depression (Leonard & Maes, 2012). And two randomized controlled trials have 
demonstrated that the administration of endotoxins in order to induce an inflammatory 
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state lead to the expression of depressive like symptoms (Grigoleit et al., 2011; 
Reichenberg et al., 2001).  
Vitamin D may act as an anti-inflammatory in the brain keeping harmful 
proinflammatory cytokines in check, and vitamin D deficiency has been linked to 
proinflammatory disease (Harms et al., 2011; Raedler, 2011). It is also possible that as a 
result of vascular changes in pregnancy the maternal cerebral environment is more 
vulnerable to inflammation perhaps explaining in part the link between vitamin D and 
depression in pregnancy (Cipolla, 2013). In light of the inflammatory nature of 
depression and the strong role of vitamin D as an anti-inflammatory and 
immunomodulator, inflammation may mediate the relationship between vitamin D and 
depression in pregnancy (Figure 4) (Arora, C. 2011; Arora et al., 2011; Guillot et al., 
2010; Hoeck & Pall, 2010; Lumeng & Saltiel, 2011; Cassidy-Bushrow et al., 2012).  
study. These hypotheses remain only theoretical and the biological explanation for the 
link between depression and low vitamin D levels is currently unknown. 
Pregnant women are experiencing an increased incidence of depression in the 
perinatal period.  A concern over vitamin D deficiency in pregnancy is growing. Recent 
evidence suggests an association exists between depression and low vitamin D levels 
(Brandenbarg et al., 2012; Cassidy-Bushrow et al., 2012; Eskandari et al., 2007; Hoang et 
al., 2011; Hoogendijk et al., 2008; Jorde et al., 2008; Murphy et al., 2010; Wilkins et al., 
2006) but due to many methodological issues in prior works the evidence is limited and 
inconclusive.  Given the current state of the science in this area, a study exploring the 
relationship between depression and vitamin D in pregnant women was undertaken for 
this dissertation. Using the proposed framework as a guide, this study explored 
   
70 
longitudinal associations between vitamin D and level of depressive symptoms across 
pregnancy.   The primary hypothesis of the study was:  There is an inverse association 
between vitamin D and depressive symptoms in a sample of pregnant women. As vitamin 
D levels decrease, depressive symptoms will increase during pregnancy.  
 
   
71 
CHAPTER III 
 
METHODOLOGY 
 
In light of the disease burden of depression and vitamin D deficiency in pregnancy, 
the current evidence and related significance of a possible association between vitamin D 
and depression in pregnancy, a longitudinal cohort study investigating the association 
between levels of vitamin D and depressive symptoms in pregnancy was conducted. A 
detailed description of the methodology is described in this chapter. Key aspects of study 
methodology are reviewed and include: study design, setting, sample, procedures, 
instruments, and analysis.  
Research Design 
An observational longitudinal cohort design was used for this study. 
 
Description of Research Setting 
  The research setting for participant recruitment and data collection was Cedars-
Sinai Medical Center in Los Angeles, California. Cedars-Sinai Medical Center is a large 
Jewish urban non-profit tertiary health care facility located in Los Angeles California 
adjacent to the city of Beverly Hills. Cedars-Sinai has a large ethnically diverse obstetric 
population. The Cedars-Sinai Medical Group outpatient obstetric and gynecologic care 
clinic and the obstetrical unit at Cedars-Sinai Medical Center were the sites used during 
the study.  The Obstetric and Gynecology Clinic is staffed by the Cedars-Sinai Medical 
Group obstetricians/gynecologists (from the Cedars-Sinai Department of Obstetrics and 
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Gynecology) and a physician assistant, and is within one mile of the Cedars-Sinai 
Medical Center.  
 
Sample and Sampling Plan 
Nature and Size of Sample 
A total of 126 participants were enrolled in the study between January 2013 and 
April 2013.  One hundred and twenty-five (N=125) women completed baseline data 
collection (time 1). One participant completed the informed consent process, but did not 
complete time 1 data collection and subsequently requested to be withdrawn completely 
from the study. She noted her husband did not want her to participate.   
A total of 96 women completed all data collection points. Figure 6 depicts the 
recruitment and retention process of study participants.  Following time 1, a second 
participant withdrew citing she was too busy to continue participation, one woman 
decided to terminate her pregnancy, three women delivered at an outside location, six 
women were unable to be contacted for the time 2 EPDS, and seven women did not have 
their time 2 blood collected for a variety of reasons (e.g., precipitous delivery). 
Additionally, ten women were removed from the sample following miscarriage or 
stillbirth in light of the strong influence this would likely have on their mood. Finally, 
one sample failed to yield a 25OHD result upon laboratory analysis.  
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Figure 6. Recruitment and Retention Process 
 
  
 Sample size was estimated based on a review of available literature examining 
associations between vitamin D and depression, and an understanding of the clinical 
importance of an association between vitamin D and depression. Sample size was 
estimated to detect a Pearson correlation of 0.25 between vitamin D levels and depressive 
symptoms scores. It was felt that a correlation of 0.25 indicated a valuable finding in 
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regards to the association between depression and vitamin D and that a correlation of less 
than 0.25 would not be large enough to represent clinical importance. A one tailed test 
estimate based on a correlation of 0.25 indicated a sample size of 100 participants would 
yield ≥ 80% power at a 0.05 significance level.  For a two-tailed test correlations of 0.25 
indicated a sample size of 125 participants would yield ≥80% power at a 0.05 
significance level. A goal was set and achieved to enroll 125 women in order to detect a 
small correlation and allow for two-tailed analysis and some attrition. However, only 96 
of the 125 women completed data for all time points.  
 
 
Criteria for Sample Selection 
To be eligible for study participation, women had to be 18 years of age or older, 
with a confirmed pregnancy at less than 25 weeks gestation, and receiving prenatal care 
at the Cedars-Sinai Medical Group obstetric and gynecology clinic. Women were 
excluded from the study if they had parathyroid disease, uncontrolled thyroid disease, or 
severe pre-existing mental illness other than depression. Exclusion of women with 
parathyroid and uncontrolled thyroid disease was necessary because these women may 
have low vitamin D levels due to disease pathology. Women with severe pre-existing 
mental illness other than depression (e.g., schizophrenia) were excluded. Severe pre-
existing mental illness other than depression can make it difficult to distinguish this 
disease from depressive symptoms. Women with or without existing depression were 
included. The presence or absence of depression or taking an antidepressant in a potential 
participant did not impact a potential participant’s eligibility for the study.  
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Study Staff 
 The study team for this research project included Amy Lamb, Dr. Calvin Hobel, 
two research nurses, two anesthesia obstetric fellows, and four research assistants. This 
author is principal investigator for this study and is listed as such at Vanderbilt 
University.  Due to restrictions on nurse researchers at Cedars-Sinai Dr. Hobel is listed as 
the principal investigator at Cedars-Sinai and this author is listed as Co-investigator. Dr. 
Calvin Hobel is a NIH funded senior researcher at Cedars-Sinai with experience in 
maternal child research and research involving vitamin D. Both of the research nurses are 
experienced in conducting maternal and child research and have current California 
registered nursing licenses. Two anesthesiologists currently in their obstetrical fellowship 
at Cedars-Sinai Medical Center participated in chart abstractions. Research assistants 
involved in the study had bachelors’ level degrees or higher and met requirements for 
research assistants working or volunteering at Cedars-Sinai Medical Center, including 
ethical human research orientation and training.   
All study staff members underwent ethical research training through the online 
collaborative IRB training initiative (CITI) program, included on the IRB application as 
key study personnel, and familiarized with the study.  All study staff members, except the 
two anesthesiologist who did not directly interact with participants, were trained on 
administering the Edinburgh Postnatal Depression Scale to pregnant women and were 
instructed one-on-one by this PI as to the protocol for responding to suicidal participants.  
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Methods for Subject Recruitment 
Several strategies were used to recruit study participants. IRB approved flyers 
announcing the study were placed in the waiting room and exam rooms at the obstetric 
and gynecologic offices of the Cedars-Sinai Medical Group. Obstetric providers were 
informed of the study and given information to refer interested patients to the study. An 
announcement of the study was also placed on the Cedars-Sinai Medical Center 
Obstetrics and Gynecology Research website. Only two women responded to flyers; one 
was found to be ineligible and one declined to participate. Neither flyers nor physician 
referral resulted in the recruitment of study participants.  
To facilitate recruitment, potentially eligible women were identified using patient 
appointment lists in the electronic medical record (Epic) CS-Link at Cedars-Sinai 
obstetric clinics. The appointment lists indicated gestational age based on a self-reported 
last menstrual period or expected delivery dated (EDD) defined by first or second 
trimester ultrasound, maternal date of birth, and visit type (e.g., first obstetric visit). A 
clinic nurse provided an initial introduction to the study and then asked women if they 
would be interested in talking with a research nurse representing the study about further 
study information. All women who expressed an interest in further study information 
were approached at the clinic and invited to participate if determined to meet eligibility 
criteria for the study.  Due to clinic and investigator concerns regarding protecting private 
patient information, study staff did not retain data on women who declined to participate 
in the study. 
A trained research nurse or this principal investigator reviewed a complete 
description of the study with all eligible women who demonstrated interest in the study. 
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All participants were fully informed both verbally and in writing regarding the study 
purpose, risks and benefits, alternatives, and right to refuse or leave. All women agreeing 
to participate completed a written informed consent process. A trained department 
research nurse or this principal investigator obtained written informed consent for all 
enrolled participants. The consent form was reviewed and women were given the 
opportunity to ask questions and all questions were answered. For consenting women the 
consent form was signed by both the participant and witnessed by the consenting study 
staff member. A copy of the consent form was given to all participants and a copy 
retained for the study records.  For non-English speaking potentially eligible women an 
IRB approved short form consent form and an interpreter were available. However no 
non-English speaking women were identified during the recruitment process.  
 
 
Data Collection Methods 
Study Procedures 
  Table 1 provides an overview of data collection procedures and time-points. Data 
collection began immediately after women completed the informed consent process with 
completion of a study questionnaire, the Edinburgh Postnatal Depression Screen (EPDS) 
and a drawn blood sample (Time 1).  A study nurse was available to answer participant 
questions. One woman had her blood drawn at her follow-up clinic visit 3 days later due 
to needing to leave for personal reasons at her enrollment visit.  
 Data collection for Time 2 occurred between 12 to16 weeks from the time of 
enrollment in the study.  Participants received a phone call from a study nurse or this 
investigator to complete both the time 2-study questionnaire and a second EPDS during 
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the phone call.  Despite efforts to reach all participants by phone prior to delivery, nine 
women had their second study questionnaire and EPDS collected during their hospital 
admission for delivery or immediately postpartum. At time of admission for delivery of 
their infant, a second maternal blood sample was collected (Time 2 blood).  Following 
study completion and using a standardized clinical abstraction form, participants’ medical 
records were abstracted and data stored. Details involving chart abstractions are described 
in the instrument section of this chapter.   
Most women (53%, N=66) were enrolled into the study in their first trimester (≤ 
13.9 weeks) and had their Time 2 data questionnaire and EPDS in their third trimester 
(Mean (SD) 31.5 (6.3) weeks (wks)). Time between depressive symptom screens (EPDS) 
was approximately 16 weeks between Time 1 and Time 2 (16.8 (4) wks). Time between 
blood draws for vitamin D level measurements was on average 16 weeks (16.2 (4.7) wks) 
between Time 1 and Time 2. Average time between EPDS at Time 2 and vitamin D level 
at Time 2 was 7 weeks (7 (5.9) wks).  
 
Table 1. Study Procedures and Time Points 
 
Procedures 
 
Time 1 
<25 wks 
gestation 
(N=125) 
 
Time 2 
EPDS 12-
16 wks from 
Time 1 and Blood 
at Delivery 
Study Questionnaires that included the EPDS and 
Demographic and Clinical Information X X (N=110) 
Blood draw/serum collection to measure Vitamin D 
(25OHD)  X X (N=109) 
Chart abstraction  X (N=125) 
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Human Subjects Protections and Data Safety 
 Human subjects protection. The population of interest was pregnant women 
who are considered to be a vulnerable group by the Department of Health and Human 
Services (DHHS) (DHHS, 2009). The ethical principles of beneficence, justice and 
respect for persons guided the development of several strategies to protect participants’ 
from any harm.  Overall, the study posed minimal risk to participants and their fetus. 
Study procedures posed no risks greater than women would encounter as part of their 
routine prenatal care.  Some minor risks were considered. 
 The minor risks involved in the study concerned screening women for depressive 
symptoms, blood sampling, and protecting personal health information. Screening for 
postpartum depression is the current standard of care.  In addition, the American 
Congress of Obstetricians and Gynecologists has stated that prenatal screening for 
depression should be strongly considered by providers (ACOG, 2010).  Depression 
screening raises the ethical question of not placing undue distress on participants and 
having safety plans and referral mechanisms in place should participants report 
thoughts/intentions for self-harm (Chaudron et al., 2007). In this study women were 
considered positive or at risk for suicidal ideation if they reported anything besides 
“never” to item 10 “the thought of harming myself has occurred to me” on the EPDS.   
Study staff identified two women who screened positive or at risk for suicidal 
ideation at the clinic or the hospital. Both women had their primary obstetrician notified 
immediately, and they were referred to the Cedars-Sinai emergency department for 
assistance. Additionally, another woman noted positive suicidal ideation during a phone 
interview.  Study staff immediately notified her obstetrician and she was referred to the 
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Cedars-Sinai emergency department.  All of the women who screened positive for 
suicidal ideation denied immediate thoughts of self-harm at that time and none of them 
had a plan. Women at risk for suicidal ideation were also given the number of the 
National Suicide Prevention Lifeline (1-800-273-TALK), which is a free accredited crisis 
hotline. No adverse events occurred in this study.  
 A small risk existed related to the blood draws to measure vitamin D levels. 
Screening for blood levels of vitamin D is not currently standard of care and the data 
concerning the value of knowing vitamin D status is conflicting. Whenever possible 
blood was drawn at the same time that other labs were being collected as part of standard 
prenatal care; however, separate blood draws were conducted when the sample was not 
collected as part of standard care. Registered nurses at the clinic and hospital as well as 
the research nurse drew blood using standard venipuncture methods. 
 A small risk related to patient privacy was considered. Participant protected health 
information was collected via self-report on study questionnaires and chart abstraction; 
however efforts were made to minimize risk involved with collecting and accessing 
protected information. Further details regarding data management/safety are described in 
the section below.  
  IRB approval for the study was received from Cedars-Sinai Medical Center and 
Vanderbilt University.  The informed consent process clearly outlined to participants that 
they could still receive their regular prenatal care regardless of study participation and 
that the study was not part of routine prenatal care. Subjects were given a $10 gift card at 
the time of enrollment and another $10 gift card at the time of study completion.  All 
study activities with participants were conducted in a private area in order to protect 
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participants’ privacy and maintain confidentiality.  All study protocols approved by the 
IRB were followed. 
   
 Data Management and Safety Monitoring Plan. To ensure participant privacy, 
blood samples and questionnaires were labeled with the participants’ study identification 
numbers (ID) instead of their names.  All databases with study ID numbers and patient 
names were encrypted and kept locked in the research office at Cedars-Sinai East Tower, 
suite 1001.  Study ID numbers were used as much as possible in place of participants’ 
names.  Collected data were entered into a password protected and encrypted REDCap 
database. No identifiable health information was stored on personal computers, laptops, 
or external drives. Only trained and IRB approved study staff had access to participant 
information. Access to identifying information was restricted and only accessed by 
necessary personnel. Physical documents containing data on research participants were 
stored in locked file cabinets in locked research offices. Research computers were 
encrypted and password secured. A data safety monitoring plan/committee was not 
required by the IRB for this study.	  
 
Instruments 
 Study Questionnaires. The questionnaires included socio-demographic and 
prenatal questions related to maternal age, ethnicity, marital status, annual income, years 
of education, height, pre-pregnancy and current weight, if the pregnancy was planned or 
not, and current medications/supplements they were using (Appendix A).  Study staff 
recorded the season during which the questionnaires, EPDS, and blood samples were 
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collected. Seasons were categorized as Summer/Fall including the months of July to 
December and Winter/Spring including January to June based on the reported number of 
clear sunny days in Los Angeles city (Western Regional Climate Center, 2010).  
 Edinburgh Postnatal Depression Scale. The 10-item Edinburgh Postnatal 
Depression scale (EPDS; Cox, Holden, & Sagovsky, 1987) was used to measure 
depressive symptoms (Appendix B). Originally, the EPDS was designed to screen for 
depression in the postpartum period (up to eight weeks postpartum; Cox et al., 1987), but 
has subsequently been validated for use during pregnancy (Cox, Chapman, Murray, and 
Jones, 1996; Lee et al., 2001; Murray & Carothers, 1990; Su et al., 2007; Yonkers, Smith, 
Gotman, & Belanger, 2009).  
 The EPDS was self-administered or given orally by a trained study staff member 
if the interview was conducted over the phone. Respondents were asked to rate each of  
the 10 items using four possible responses that were subsequently scored 0 – 3. Each 
response corresponded to a level of intensity of depressive symptomatology (Cox et al., 
1987). A total score was calculated by tallying responses for each of the items, with items 
3, 5, 6, 7, 8, 9, and 10 being reverse scored (Cox et al., 1987). The total possible score for 
the EPDS ranges from 0 to 30 with cut-off scores listed in the literature between 9 to 15 
and/or a positive response to item 10, suicidal ideation, correlating with depression (Cox 
et al., 1987; Murray & Carothers, 1990; Sit & Wisner, 2009). Many studies note a cut-off 
score of 9, which yields a broad range of reported sensitivity (68-80%) and specificity of 
77% (Murray & Carothers, 1990; Lawrie, Hofmeyr, de Jager, & Berk, 1998) to 
distinguish between depressed and non-depressed women. In order to identify all women 
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with possible major or minor depression a cut-off score of 9 was employed in this study 
(Cox et al., 1987).   
  The EPDS was chosen for this study for its accuracy and ease of use. In a large 
meta-analysis examining several different measures for perinatal depression the EPDS 
was found to have higher sensitivity for detecting major depression than other scales 
(Hewitt et al., 2009). The EPDS can be completed quickly and is generally well accepted 
by participants (Cox et al., 1987; Hewitt et al., 2009).  The EPDS demonstrates good 
convergent validity and is moderately correlated with both the BDI and CES-D. The 
calculated Cronbach’s alpha for the EPDS in the current study was α=.82. Other studies 
have employed the EPDS to examine associations between vitamin D and postpartum 
depression (Murphy et al., 2010; M. Robinson et al., 2014).  
 25OHD. 25-hydroxyvitamin D (25OHD) was used to measure vitamin D levels in 
maternal blood samples.  Trained nurses drew maternal blood samples using standard 
venipuncture methods. Whole blood was collected into serum separator tubes. Blood 
samples were spun and frozen or refrigerated and then spun and frozen within an average 
of 48 hours from time of collection.  Some degree of mild to moderate hemolyzation was 
noted for 54 samples. Hemolysis at moderate levels has been shown to not influence test 
results, however at severe levels it made lead to slight under estimation of vitamin D 
levels (Nowak et al., 2011). After being centrifuged for a minimum of 15 minutes serum 
was aspirated and alliqoted to 1-2 ml cryotubes. Cryotubes were frozen at -20° C and 
then hand carried packed in dry ice to Endocrine Sciences, Esoterix Inc., a part of 
LabCorp Specialty Testing Group in Calabasas Hills, CA, 91301. At the lab, samples 
were thawed and analyzed by LC-MS/MS using a Thermo® ARIA® TX-4 HPLC system 
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with Agilent® 1200SL pumps and a Sciex® API5000 triple quadrupole mass 
spectrometer. A Supelco® PFP analytical column was used (100 x 2.1mm, 2.7um, 100A) 
with a water:methanol gradient to achieve full baseline chromatographic separation of 
epimer and non-epimer forms of each analyte. Independent calibration curves were 
prepared for all metabolites. Calibration was performed using UV/Vis spectrophotometry 
and was further verified using reference materials from NIST as well as 3rd party 
vendors. Sample preparation consisted of isotope dilution using the internal standards 
25OHD2-2H3, 25OHD3-2H6, protein precipitation and liquid-liquid extraction. Both 
25OHD3 and 25OHD2 were measured in this study, however similar to the study by 
Nielsen et al (2013) 25OHD2 values were found to be non-contributory and therefore only 
25OHD3 values are reported. Vitamin D levels were processed at the end of the study in 
order to keep study staff and participants blinded to the levels during the study. 
 Chart Abstraction. Additional maternal and infant data were abstracted from the 
participant’s electronic medical record stored on CS-Link (Epic) system. Abstracted data 
included: delivery information such as infants’ gestational age at time of delivery, mode 
of delivery, and neonatal outcomes.  This PI and the two anesthesiology fellows working 
with the study completed the chart abstractions. Collected data were then entered into the 
password protected REDCap database for management and storage.  
 
Data Analysis 
 Descriptive and inferential statistics were used for analysis of study data. 
Descriptive statistics (e.g., means, standard deviations, interquartile ranges, percentages) 
were used to describe the sample characteristics. Women who enrolled in the study were 
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dichotomized into groups by sufficient (25OHD ≥30ng/ml) and insufficient (25OHD 
<30ng/ml) vitamin D levels to help describe the study sample, and independent t-tests 
and chi-square values are reported for significant differences between groups for 
bivariate analyses. Paired t-test and Wilcoxon Signed Rank tests were used to evaluate 
differences between early and late pregnancy vitamin D levels and depressive symptom 
scores within the total sample group. Correlations between 25OHD3 and EPDS sum 
scores were analyzed for the total sample. Both Pearson product moment and Spearman’s 
rho correlations were evaluated. Correlations are reported for all time points. 
In order to test the hypothesis of whether low vitamin D levels lead to an increase 
in depressive symptoms, a two-step linear regression was conducted. Two analyses were 
analyzed to help determine the temporal precedence of the association (i.e., did early low 
levels of vitamin D predict higher levels of depressive symptoms or vice versa?). The 
first model was analyzed using the EPDS Time 2 sum scores as the dependent variable; 
then, Time 1 EPDS sum scores and Time 1 vitamin D levels were added in a stepwise 
fashion. To assess for the obverse of the hypothesis (i.e., high depressive symptoms lead 
to low vitamin D), a second regression analysis was analyzed.  The second two-step 
linear regression included vitamin D Time 2 levels as the dependent variable, and then 
introduced Time 1 vitamin D levels on step 1 and Time 1 EPDS sum scores on step 2.  
Additionally, a two-step hierarchical multiple linear regression model was 
evaluated to control for the influence of possible confounding variables. This model used 
Time 1 EPDS scores as the dependent variable. Four possible confounders (BMI, years of 
education, ethnicity, and unplanned pregnancy) were added as independent variables in 
step 1 followed by 25OHD3 Time 1 levels in step 2.  SPSS 22.0 was used for all 
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statistical analyses, and a two-tailed α = 0.05 level of significance was used for all 
statistical tests.  
 
Missing Data 
 Missing and incomplete data were present in this study. Several (N= 30) women 
did not complete all data collection points. Three women did not answer one or two of 
the questions on the EPDS.  For these three EPDS questionnaires computational means 
based on other items from the same screen were used to impute missing values. These 
women were included in the final analysis. Using the computational mean as a substitute 
for the missing values when there are a minimal number of missing values can be an 
effective method of addressing missing data in summative rating scales, although it may 
introduce some bias (Raaijmakers, 1999).  
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CHAPTER IV 
 
RESULTS 
 Statistical analysis of data yielded a number of important study results. Findings 
from the longitudinal cohort study on the association between vitamin D and depression 
in pregnancy are discussed in regards to sample characteristics, study questions, and 
study hypothesis. Additional findings not directly related to the primary hypothesis and 
questions are briefly reviewed.  
 
Sample Characteristics 
 Table 2 depicts the clinical and demographic characteristics for the total sample 
and for subgroups of women by vitamin D level (i.e., sufficiency or insufficiency).  
Overall, this ethnically diverse sample of 125 women tended to be older, overweight or 
obese, upper class, well educated, married, having planned their pregnancy, and working. 
Most women in the study delivered at term and no women in the sample smoked (N=0).  
Approximately, one fourth of women (N= 32) reported elevated depressive symptoms 
(25.6% with mean EPDS sum score ≥ 9) and approximately two-thirds (N = 83) had 
vitamin D insufficiency (66.4% at 25OHD3  < 30 ng/ml) in the total sample. The 
characteristics of the final sample of 96 women (i.e. those with complete data for both 
time points) were similar to the total sample (N=125).  Women who were excluded from 
the final sample (N=29) due to incomplete data for both time points for any reason (e.g., 
fetal demise, miscarriage, withdrew, delivered at outside of hospital) were more likely to 
be unmarried (χ2 =8.95, p=0.030) and of ethnic minority (χ2 =11.5, p=0.042) as compared 
to the final sample (N=96).  
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Table 2. Participant characteristics for total and final samples 
a Mean (SD); b For the total sample (N=125) only time 1 values are reported, but for the final 
sample (N=96) the mean of Time 1 + Time 2 is reported.  
 
 
	   Total	  
(N=	  125)	  
Total	  
(N=	  96)	  
Variable	   Median	  (IQR)	   Median	  (IQR)	  
Age	  (yrs)	   33	  (31-­‐36.5)	   33	  (31-­‐36)	  
BMI	  	  
	  	  	  	  Normal/Underweight	  (≤	  24.9)	  
	  	  	  	  Overweight	  (25-­‐29.9)	  
	  	  	  	  Obese	  (≥	  30)	  
25	  (23-­‐29)	  
39.2%	  (49)	  
38.4%	  (48)	  
22.4%	  (28)	  
25	  (23-­‐28)	  
41.7%	  (40)	  
37.5%	  (36)	  
20.8%	  (20)	  
Annual	  Household	  Income	  ($)	  (104)	  	   103,295k	  (50k-­‐120k)	   87.5k	  (50k-­‐150k)	  
Education	  (years	  )(117)	   16.4	  (2.5)a	   16.4	  (2.5)a	  
Parity	  	   2	  (1-­‐3)	   2	  (1-­‐3)	  
Estimated	  Gestational	  Age	  (EGA)	  at	  time	  of	  Delivery	   39.4	  (38.4-­‐40.1)	   39.6	  (38.7-­‐40.3)	  
EPDS	  Sum	  Scoreb	   5.7	  (4.1)a	   5.6	  (3.5)a	  
Vitamin	  D	  Level	  (25OHD3)
b	   26.1	  (9.2)a	   25.8	  (9.1)a	  
	   Percent	  (N)	   Percent	  (N)	  
Marital	  Status	  
Single	  
Partner	  (Not	  Cohabitating)	  
Living	  with	  Partner	  
Married	  	  
Divorced	  	  
	  
3.2%	  (4)	  
1.6%	  (2)	  
16%	  (20)	  
79.2%	  (99)	  
-­‐-­‐-­‐-­‐-­‐-­‐	  
	  
2.1%	  (2)	  
2.1%	  (2)	  
11.5%	  (11)	  
84.4%	  (81)	  
-­‐-­‐-­‐-­‐-­‐-­‐	  
Ethnicity	  
Asian	  
Black/AA	  
Caucasian	  
Hispanic	  
Indian	  
Mixed	  
	  
16.7%	  (21)	  
19%	  (24)	  
32%	  (41)	  
21.4%	  (27)	  
4.8%	  (6)	  
4.8%	  (6)	  
	  
13.5%	  (13)	  
17.7%	  (17)	  
37.5%	  (36)	  
24%	  (23)	  
2.1%	  (2)	  
5.2%	  (5)	  
Employment	  
No	  	  
Yes	  
	  
26.4%	  (33)	  
73.6%	  (92)	  
	  
28.1%	  (27)	  
71.9%	  (69)	  
History	  of	  Depression	  
No	  	  
Yes	  
	  
91.2%	  (115)	  
8.8%	  (11)	  
	  
92.7%	  (89)	  
7.3%	  (7)	  
Illicit	  Drug	  Use	  
No	  	  
Yes	  
	  
97.6%	  (122)	  
2.4%	  (3)	  
	  
97.9%	  (94)	  
2.1%	  (2)	  
Do	  you	  currently	  drink	  alcohol?	  
No	  	  
Yes	  
Amount	  (drinks/week)	  
	  
96.7%	  (117)	  
3.3%	  (4)	  
1.19	  (1.88)a	  
	  
94.8%	  (91)	  
3.1%	  (3)	  
1.6	  (2.1)a	  
Planned	  Pregnancy	  
No	  	  
Yes	  
	  
28.8%	  (36)	  
71.2%	  (89)	  
	  
27.1%	  (26)	  
72.9%	  (70)	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Analysis of Research Questions and Hypothesis 
 Study findings are organized by research questions and study hypothesis.  
Research Questions 
 Is there a difference between early and late pregnancy vitamin D levels? Time 1 
and Time 2 vitamin D levels were moderately correlated in this study (r=0.67, p <0.001). 
A statistically significant difference between Time 1 vitamin D levels and Time 2 vitamin 
D levels (Mean 25OHD3 Time 1=25.8 vs. Time 2= 34.1 ng/ml; paired t= 10.04, p 
<0.001) emerged from the paired t-tests analysis. Late pregnancy (Time 2) vitamin D 
levels were higher than vitamin D levels in early pregnancy (Time 1).  A significant 
difference between early and late pregnancy vitamin D levels was observed in this 
sample. 
Is there a difference between early and late pregnancy depressive symptoms? 
Early (Time 1) and late pregnancy (Time 2) EPDS sum scores were also moderately 
correlated in this sample (r=0.63, p <0.001). A paired t-test was used to evaluate for 
differences between Time 1 and Time 2 depressive symptoms scores. There was no 
statistically significant difference found (Mean EPDS sum scores Time 1 = 5.5 vs. Time 
2 = 5.7; paired t=0.51, p=0.611). No differences between depressive symptoms in early 
and late pregnancy were observed in this sample.  
Is there a relationship between vitamin D levels and depressive symptoms during 
pregnancy?  Results of a correlational analysis that examined the level of association 
between EPDS scores and vitamin D levels at all time points are depicted in Table 3. 
Time 1 EPDS sum scores and Time 1 vitamin D levels showed inverse associations for 
both the total original sample (N=125; r=-0.152, p=.092) and the final reduced sample 
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(N=96; r=-0.236, p=.020), but the association was only significant in the final sample. 
Significant inverse associations were noted between Time 2 EPDS scores and Time 2 
vitamin D levels (r = -.321; p=.001). Also, a significant inverse association was observed 
between overall mean EPDS sum scores (5.6) and overall mean vitamin D levels (29.9) in 
the final sample (N=96; r =-.334; p=.001). In addition women with insufficient vitamin D 
tended to have higher mean depressive symptom sum scores (6.7 (3.6) vs. 4.8 (3.5); t=-
3.02, p = .003) and women with elevated depressive symptoms had lower mean 25OHD3 
levels (26.4 vs. 30.9 ng/ml; p=.047).  Therefore, a significant relationship between 
vitamin D levels and depressive symptoms during pregnancy was observed in this 
sample.  
 
Table 3.  Correlations between levels of depressive symptoms and vitamin D by time 
point for the final sample (N=96). 
 
Predictive Hypothesis 
 A regression analysis was conducted to test the primary hypothesis that low 
vitamin D levels may lead to higher depressive symptoms. A two-step regression was 
analyzed using EPDS Time 2 as the dependent variable, controlling for EPDS at Time 1. 
The addition of baseline vitamin D to the regression model on step 2 did not add a 
statistically significant amount of explanatory power (R2 = .392 model 1, R2 = .409 model 
        EPDS Time 1 EPDS Time 2 25OHD3 Time 1 25OHD3Time 2 
 r (p-value) 
EPDS Time 1 1 .658 (< .001) -.236 (.020) -.289 (.004) 
EPDS Time 2 ----- 1 -.267 (.009) -.321 (.001) 
25OHD3 Time 1 ----- ----- 1 .668 (< .001) 
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2, Δ R2 =.017, p= 0.102). Thus, this finding did not support the hypothesis that low levels 
of vitamin D lead to increased depressive symptoms.  
 A second regression was conducted to assess the reverse hypothesis (i.e., 
increasing depressive symptoms lead to decreases in vitamin D levels), and yielded 
similar null results (R2 = .446 model 1, R2 = .456 model 2, Δ R2 = 0.010, p= 0.202.  
 
Adjusting for Covariates 
 A final regression model was evaluated to control four possible confounding 
variables: BMI, years of education, ethnicity, and whether the pregnancy was planned or 
unplanned. Those variables were chosen based on prior literature and significant 
associations with either EPDS or 25OHD in this sample. Time 1 EPDS and 25OHD3 
values for all 125 women in the initial sample were used for this regression.  The 
correlation between Time 1 25OHD3 and Time 1 EPDS sum scores for the total sample 
(N = 125) was significant in the regression model as a one-tailed test (r = -.152; p = 
.046), but when covariates were included in the model, 25OHD3 only accounted for a 
small, non-significant increase in explanatory power (1%) for EPDS sum scores (R2 = 
.030 model 1, R2 = .039 model 2, Δ R2 =.010, p=.272).  
Other Findings 
 Women were dichotomized into two subgroups, sufficient and insufficient 
vitamin D levels (25OHD3 ≥ 30ng/ml vs. 25OHD3 < 30ng/ml), based on mean vitamin D 
levels aggregated across both time points (Table 4). Women with insufficient vitamin D 
tended to have higher BMIs (t=-2.03, p =.045), fewer years of education (t=2.04, p 
=.044), were more likely to have darker skin tones (e.g., Black, Indian, and Hispanic) (χ2 
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=8.29, p=0.008), and have an unplanned pregnancy (χ2 =5.28, p=0.022) as compared to 
women with sufficient vitamin D levels. In the final sample (N=96) women with elevated 
depressive symptoms were more likely to report a history of depression (20% vs. 4%; 
p=.014), and be unemployed (50% vs. 22.4%; p=.014).  There were no statistically 
significant differences in women with elevated depressive symptoms in the final or total 
sample for BMI, ethnicity, unplanned pregnancy, and years of education. There were also 
no differences between women who had their Time 2 EPDS collected at time of delivery 
as compared to those who were screened at 12-16 weeks from Time 1 (t=-2.93, 
p=0.770).  
 Some additional findings of interest were noted related to gestational age and 
blood loss at time of delivery. Vitamin D levels were positively correlated with 
gestational age at time of delivery for both mean (r=0.28, p= .006) and Time 2 vitamin D 
values (r=.247, p= .015).  Women who hemorrhaged at delivery (blood loss ≥ 500 cc; N 
= 22) had significantly lower 25OHD3 levels at Time 2 (delivery) (M = 29.6) as 
compared to women who did not hemorrhage (M = 35.4; t=-2.23, p= 0.03).  
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Table 4. Participant characteristics by sufficient and insufficient vitamin D levels 
 Vitamin	  D	  Sufficiency	  25OHD3	  
≥30ng/ml	  (N=48)	  
Vitamin	  D	  Insufficiency	  25OHD3	  
<30ng/ml	  (N=48)	  
p-­‐value 
Variable	      
Age	  (yrs) 33.8	  (4.2) 32.7	  (5.4) .256 
BMI	  	   25.2	  (3.9) 27.1	  (5.4) .045* 
Annual	  Household	  Income	  	  	  
($)	  (82)	   
126k	  (121k) 98k	  (84k) .226 
Education	  (years)	   16.9	  (2.7) 15.9	  (2.1) .044* 
Parity	   2.2	  (1.5) 2.5	  (1.4) .425 
Estimated	  Gestational	  Age	  
(EGA)	  at	  time	  of	  Delivery 
39.6	  (1.5) 38.9	  (1.7) .055 
Mean	  EPDS	  sum	  scores	   4.5	  (3.4) 6.6	  (3.4) .003* 
	   %	  (N)	   %	  (N)	   	  
Marital	  Status	  
Single	  
Partner	  
Living	  with	  Partner	  
Married	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Divorced	   
	  
0%	  (0)	  
2.1%	  (1)	  
6.3%	  (3)	  
91.7%	  (44)	  
-­‐-­‐-­‐-­‐-­‐-­‐ 
 
	  
4.2%	  (2)	  
2.1%	  (1)	  
16.7%	  (8)	  
77.1%	  (37)	  
-­‐-­‐-­‐-­‐-­‐-­‐ 
	  
.181 
Ethnicity	  
Asian	  
Black/AA	  
Caucasian	  
Hispanic	  
Indian	  
Mixed 
	  
12.5%	  (6)	  
10.4%	  (5)	  
52.1%	  (25)	  
16.7%	  (8)	  
2.1%	  (1)	  
6.3%	  (3) 
	  
14.6%	  (7)	  
25%	  (12)	  
22.9%	  (11)	  
31.3%	  (15)	  
2.1%	  (1)	  
4.2%	  (2) 
	  
.008* 
Employment	  
No	  	  
	  	  	  Yes 
	  
25%	  (12)	  
75%	  (36) 
	  
31.3%	  (15)	  
68.7%	  (33) 
	  
.496 
History	  of	  Depression	  
No	  	  
Yes	  
	  
93.8%	  (45)	  
6.3%	  (3)	  
	  
91.7%	  (44)	  
8.3%	  (4)	  
.695	  
Planned	  Pregnancy	  
No	  	  
Yes 
	  
16.7%	  (8)	  
83.3%	  (40) 
	  
37.5%	  (18)	  
62.5%	  (30) 
.022* 
* p ≤ 0.05 
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CHAPTER V 
 
DISCUSSION 
 
 This study examined associations between levels of vitamin D and depressive 
symptoms at multiple time points in a sample of pregnant women. Overall study findings 
partially support the study hypothesis and study questions. An inverse association 
between depressive symptoms and vitamin D emerged; however, the hypothesized 
direction of the association could not be established. Results suggest that vitamin D 
insufficiency may be an important risk factor for depression in pregnancy, but we can’t 
rule out the alternative hypothesis that depressed mood might contribute to lower Vitamin 
D levels.  Study results are discussed within the context of current evidence and proposed 
relationships. Study limitations and implications are presented and recommendations for 
future research are discussed.   
 The sample of women in this study were well-educated, upper-middle class, and 
ethnically diverse. Differences in socio-demographic characteristics between women with 
sufficient and insufficient vitamin D were similar to those observed in other studies 
(Murphy et al., 2010; M. Robinson et al., 2014) and consistent with risk factors for 
hypovitaminosis D. The incidence of depression in this sample was slightly higher than 
expected (25%), however still in keeping with estimates from other studies of this nature 
(Cassidy-Bushrow et al., 2012; M. Robinson et al., 2014; Villegas et al., 2011). The 
incidence of vitamin D insufficiency was high in both the total (original) and final 
(reduced) samples (66.4% and 50%). Levels were similar to other studies investigating 
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vitamin D and depression in pregnancy (Cassidy-Bushrow et al., 2012; Murphy et al., 
2010; M. Robinson et al., 2014) and may be due to using the higher Endocrine Society 
cut-off of 30 ng/ml for insufficiency (Endocrine Society, 2011). Similar to other studies, 
women with higher depressive symptoms were more likely to have a history of 
depression and to be unemployed (Greenberg et al., 2003; Stewart et al., 2003).  
 
Discussion of Findings in Relation to Research Questions and Hypothesis 
Vitamin D Levels Over the Course of Pregnancy 
 The study sought to answer research questions about changes in vitamin D levels 
and depressive symptoms over the course of pregnancy. Current research suggests that 
25OHD values tend to be stable across all trimesters of pregnancy (Brannon & Picciano, 
2011; Marwaha et al., 2011).  However, some studies have noted a rise in 25OHD in the 
third trimester (Cross et al., 1995; Sanchez et al., 1996). In this study, Vitamin D levels at 
the time of delivery, were noted to be significantly higher than those assessed during 
early pregnancy (i.e., less than 25 weeks gestation). Similar to the study by Cross et al. 
(1995) a rise in 25OHD from early pregnancy to time of delivery may be explained by 
season at time of measurement. Baseline vitamin D levels were measured during 
Winter/Early Spring (January to April), and most delivery vitamin D levels were obtained 
in the Summer (July to September) when there are more sunny days based on the average 
number of clear sunny days in Los Angeles and the temperatures are warmer (Western 
Regional Climate Center, 2010). More sun and higher temperatures can lead to women 
wearing less clothing.  Both factors can contribute to increased skin exposure to sunlight 
thus increasing the synthesis of vitamin D with a concurrent rise of vitamin D levels in 
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the summer months. Another possible explanation for the rise in vitamin D levels from 
early to late pregnancy could be initiation of prenatal vitamins. However, this explanation 
is questionable since the limited amount of vitamin D present in standard prenatal 
vitamins has been shown to be inadequate for raising 25OHD levels in pregnant women 
(Hollis et al., 2011).  
 
Level of Depressive Symptoms Over Time 
 Consistent with other studies (Brandenbarg et al., 2012; Cassidy-Bushrow et al., 
2012), levels of depressive symptoms were correlated between early and late pregnancy. 
Prior research suggests that elevated depressive symptoms in early pregnancy are a good 
predictor for late pregnancy and postpartum depression (Milgrom et al., 2008). Findings 
from this study were consistent with the literature; women with elevated depressive 
symptoms were more likely to have a history of depression. This finding provides further 
support for the chronic nature of depression. Findings from the current study underscore 
the stability of depressive symptoms across time. One unique feature of this study in 
regards to depressive symptoms was the repeated measures of vitamin D and depressive 
symptoms during pregnancy. Prior studies examining these variables have only measured 
depressive symptoms at a single time point.  
Vitamin D and Depressive Symptoms in Pregnancy 
 Results of this study indicated a statistically significant relationship between 
lower vitamin D levels in early pregnancy (T1) and higher depressive symptoms in late 
pregnancy (T2).  This finding is largely consistent with prior, although limited, findings 
(Brandenbarg et al., 2012; Cassidy-Bushrow et al., 2012; Murphy et al., 2010; M. 
Robinson et al., 2014). Vitamin D is likely not the only factor involved in the 
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development of depression in pregnancy, however it may represent an important marker 
for identifying pregnant women at risk for depression. For the most part, this relationship, 
although not statistically significant for the total sample (N=125) in early pregnancy, held 
at all other time points. The hypothesis, examined by hierarchical regression, that low 
levels of vitamin D would “account for” elevated depressive symptoms in later pregnancy 
was not supported by study findings (p=.102). Although 125 women enrolled in the 
study, complete data was only available for 96 women. The smaller sample size used in 
the regression analysis testing this hypothesis may have impacted study findings.  
Additionally, the study design did not control for pre-existing depression or 
vitamin D deficiency making it difficult to assess the temporal precedence of the 
association. Thus, the theoretical framework suggesting an inverse association between 
vitamin D and depressive symptoms was validated, however the study was not able to 
indicate whether low vitamin D proceeds increased depressive symptoms. The study was 
also unable to test for mediating effects of inflammation/neuropathology, but positive 
associations between vitamin D deficiency and BMI were noted in this sample. There is 
substantial body of evidence linking chronic inflammation with metabolic dysfunction 
(Lumeng & Saltiel, 2011; Sonnett et al., 2010; Wellen & Hotamisligil, 2005). Depression 
has been linked to metabolic disease and inflammation (Raedler, 2011; Shelton & Miller, 
2010), and vitamin D is known to have a critical role in normal metabolism and to have 
strong anti-inflammatory properties (Arora, C. 2011; Arora et al., 2011; Guillot et al., 
2010; Hoeck & Pall, 2010; Lumeng & Saltiel, 2011). Therefore, the positive association 
between vitamin D and BMI in this sample may indicate that underlying metabolically 
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mediated inflammation may have a role in the noted association between vitamin D 
deficiency and elevated depressive symptoms.   
 Several potentially confounding variables in the relationship between Vitamin D 
levels and depression have been noted in the literature: age, BMI, employment status, 
(Brandenbarg et al., 2012), educational level, ethnicity (Brandenbarg et al., 2012; 
Murphy et al., 2010), parity (Brandenbarg et al., 2012; Nielsen et al., 2013), socio-
economic status (Brandenbarg et al., 2012; Murphy et al., 2010; Nielsen et al., 2013) 
pregnancy intention, smoking (Brandenbarg et al., 2012; Nielsen et al., 2013; Robinson et 
al., 2014), social support (Nielsen et al., 2013), and marital status (Brandenbarg et al., 
2012; Murphy et al., 2010). Many of these confounding variables (e.g., BMI) are shared 
risk factors for both vitamin D and depression and may account for the association 
between them.   
Confounding variables in this study were selected based on prior literature and on 
variables found to have significant correlations with vitamin D or depressive symptoms 
in this sample. Potential confounding variables on the association between vitamin D and 
depressive symptoms were evaluated at Time 1 (e.g., BMI, years of education, ethnicity, 
and pregnancy intention). Although, none of the covariates analyzed made a statistically 
significant unique contribution to EPDS scores in this sample, the combination of these 
covariates overwhelmed the influence of 25OHD3 on EPDS scores. BMI and years of 
education accounted for most of the confounding influence on the association between 
vitamin D levels and depressive symptoms. Higher BMIs may lead to underlying 
metabolic inflammation leading to both decreases in vitamin D levels and increases in 
depressive symptoms, thus acting as a possible mediator on the relationship. Higher 
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education may lead women to eat healthier diets and exercise contributing to higher 
vitamin D levels and lower depressive symptoms possibly explaining education’s 
influence on the relationship.  
 Some unexpected but potentially significant findings occurred.  Women in this 
study who experienced hemorrhage at delivery had lower levels of vitamin D.  No studies 
were found on my review of the current literature investigating intrapartum/postpartum 
hemorrhage and vitamin D. Literature noting increased risk of stroke (Brondum-
Jacobsen, Nordestgaard, Schnohr, & Benn, 2013), bleeding during periodontal surgery 
(Bashutski et al., 2011), and need for primary cesarean section (Merewood et al., 2009) 
with vitamin D deficiency have been noted and suggest there may be a link between 
bleeding, uterine muscle dysfunction, and vitamin D deficiency. Further research is 
needed to investigate the association between hemorrhage and vitamin D deficiency.  
 
Study Limitations 
 The prospective single cohort design used in this study was appropriate for 
assessing associations between depression and vitamin D in a sample of pregnant women. 
This design allowed for the assessment of depression using a standardized depressive 
screening tool (i.e., EPDS), something that is not routinely done in the antenatal period 
and often not available in existing data sets. Measurement of levels of depressive 
symptoms and vitamin D at multiple time points allowed the study to demonstrate 
stability of depressive symptoms across time and to identify changes in vitamin D levels 
across the prenatal period, minimizing maturation threats.  This prospective design 
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allowed for the measurement and consideration of covariates of interest that may not 
have been available in a retrospective design or secondary analysis.  
 Several limitations should be considered for this study.  The relatively small 
convenience sample of women may limit the ability to detect differences and the 
generalizability of findings. Due to restrictions on enrollment methods, study staff was 
not able to collect data on women who declined to participate in the study. Thus, it was 
not possible to determine if there were significant differences between women who 
volunteered for the study and those who did not volunteer. Women in my study tended to 
be older (33 vs. 25.4 yrs) (Martin et al., 2010 National Vital Statistics) than the average 
maternal age for first birth in the United States, and have higher incomes (103k vs. 61.6k) 
(U.S. Census Bureau for California, 2010) as compared to other family household 
incomes in California, further limiting generalizability.  
 An urban setting in a developed country (e.g., United States) is an ideal location 
for examining the link between vitamin D deficiency and depression in pregnancy, since 
rates of both conditions are higher in these particular areas. However, having only one 
site in an urban location limits the generalizability of study findings and makes 
application to rural and underdeveloped regions and populations difficult. The study 
sought to examine levels of depressive symptoms and vitamin D in early and late 
pregnancy and therefore only enrolled women less than 25 weeks gestational age. As a 
result, this study does not include women who were late to enter or who had no prenatal 
care, introducing a bias towards women who seek early care and preventing the study 
from examining those with little no or care despite their increased risk for depression 
(Cypryk et al., 2008).  
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 In addition this study suffered from approximately a 24% attrition rate and some 
missing data. There are a wide variety of reasons why retention of pregnant women in 
research is so difficult (Macklin, 2010; Wisner, Appelbaum, Uhl, & Goldkind, 2009; 
Merkatz, 1998). Partly the explanation lies with pregnant women themselves as the 
pregnancy can be lost (miscarriage) or terminated and viable pregnancies take a 
significant amount of time to gestate, during which women may experience life events 
that make it difficult for them to continue study participation (e.g. relocation). The 29 
women with incomplete data for both time points, including those with 
miscarriage/stillbirth, were more likely to be single and of an ethnic minority as 
compared to rest of the sample. This may have introduced some sampling bias into the 
final sample.  
 Also, limiting this study is the use of self-report on depression screens, which is 
not a substitute for professional evaluation and diagnosis of depression. Ideally, women 
who screened positive would be examined by a mental health professional. The study 
design is observational so causality is unable to be established in the way that a more 
rigorous design may offer.  However, multiple time points of data collection provided 
some evidence for a direction of the relationships. This design was vulnerable to testing 
threats as the women were screened for depression at more than one time point. This 
repeated screening may have heightened their awareness or influenced their responses. In 
an effort to minimize this threat, data assessing levels of depressive symptoms was 
collected at least 3 weeks apart. A history threat to internal validity existed for this study 
as a result of the growing popularity of vitamin D supplementation and growing 
awareness of depression. The design used helped to minimize a history threat, because 
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the entire cohort had similar exposures to historical threats, as it was a single site study, 
same city, and relatively similar social class. The cohort was vulnerable to maturation 
threats as it examined pregnant women who were moving through stages of change 
during the course of their pregnancy. However, the entire cohort was on the same 
maturation trajectory and the repeated measures throughout the study helped to identify 
patterns regarding maturation. 
This study also did not evaluate for social support, anxiety, or life stressors, which 
may be underlying causes of elevated depressive symptoms. The study also did not 
account for dietary intake of vitamin D (e.g., fatty fish, fortified milk, etc.) and thus is 
unable to detect the role diet may have played in low vitamin D levels in this sample. 
Depression by nature can lead to poor nutrition and sedentary lifestyle, which could result 
in less vitamin D intake and synthesis, perhaps leading to lower vitamin D levels. It is 
therefore possible that high depressive symptoms may lead to low vitamin D, however 
this pattern was not universally observed in this study. The study also did not measure 
levels of vitamin D and depressive symptoms at exactly the same time at each time point. 
However, stability of depressive symptoms over the course of the pregnancy helps to 
ameliorate some of the potential bias this may have introduced. The design did not 
control for all threats to validity, but provides exploratory level data on the relationship 
between vitamin D and depression in pregnancy.  
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Implications 
 My findings support a significant association between low levels of vitamin D and 
elevated depressive symptoms in pregnancy. This study affirms previous studies that 
indicate depression and vitamin D deficiency are common in pregnancy. This study 
provides support for existing clinical guidelines that pregnant women at risk for vitamin 
D deficiency (such as those with parathyroid disease) and depression (history of 
depression) should be screened. The study also suggests that physicians and nurses may 
want to consider screening women diagnosed with depression for vitamin D deficiency 
and vice versa, although further research is needed before routine screening of depressed 
women for vitamin D deficiency can be recommended.  
As more evidence becomes available, vitamin D may come to be a meaningful 
clinical marker for depression risk in pregnancy enabling obstetricians, midwives, and 
obstetric nurses to identify women at risk for depression prior to the onset of severe 
depression. Supplementation with vitamin D may represent a safe and important adjunct 
therapy for pregnant and postpartum women diagnosed with depression. As a result of the 
caring partnership between nurses and patients, nurses and midwives are well situated to 
raise awareness and decrease stigma-surrounding depression in pregnancy, and to educate 
women about emerging research on vitamin D and depression.  
 
Recommendations for Future Research 
 This study adds to the growing but still very limited body of knowledge about 
levels of depressive symptoms and vitamin D during pregnancy. Both of these 
components are critical to the health of women and their offspring as serious 
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consequences can occur with the independent presence of either (i.e., depression or low 
levels of vitamin D). However, the examination of the relationship between the two is a 
relatively new area of research with very few studies. To this author’s knowledge this 
study is the first that includes multiple time points in the pregnancy period. The 
identification of vitamin D deficiency as a risk factor for depression in pregnancy is an 
important step towards early identification and prevention of depression among women 
in the perinatal period and beyond. Future studies should include longitudinal assessment 
across pregnancy and postpartum periods with multiple time points for data collection, 
investigation of mechanisms underlying the association (i.e., inflammation), and 
randomized trials examining the effect of vitamin D supplementation on depressive 
symptoms and other important clinical outcomes (e.g., hemorrhage) in pregnant and 
postpartum women.  
 
 
 
 
 
 
 
 
 
 
 
   
105 
Yes, quite a lot *10 The thought of harming myself has occurred to me 
 Yes, sometimes  Yes, quite often 
No, not much  Sometimes 
No, not at all  Hardly ever 
Never 
 
APPENDIX A 
Edinburgh Postnatal Depression Scale1 
(EPDS) 
 
Study ID:                                                                                          Date:                                          
 
Interviewer:                                                             
  
 
As you are pregnant or have recently had a baby, we would like to know how you are feeling.  Please check 
the answer that comes closest to how you have felt IN THE PAST 7 DAYS, not just how you feel today. 
Here is an example, already completed. 
I have felt happy: 
Yes, all the time 
Yes, most of the time This would mean: “I have felt happy most of the time” during the past week. 
No, not very often Please complete the other questions in the same way. 
No, not at all 
 
In the past 7 days: 
 
1.  I have been able to laugh and see the funny side of things  *6.  Things have been getting on top of me 
As much as I always could  Yes, most of the time I haven’t been able 
Not quite so much now  to cope at all 
Definitely not so much now  Yes, sometimes I haven’t been coping as well 
Not at all as usual 
No, most of the time I have coped quite well 
2.  I have looked forward with enjoyment to things No, I have been coping as well as ever 
As much as I ever did 
Rather less than I used to *7   I have been so unhappy that I have had difficulty sleeping 
Definitely less than I used to Yes, most of the time 
Hardly at all Yes, sometimes 
Not very often 
*3.   I have blamed myself unnecessarily when things  No, not at all 
Went wrong 
Yes, most of the time *8   I have felt sad or miserable 
Yes, some of the time  Yes, most of the time 
Not very often   Yes, quite often 
No, never Not very often 
No, not at all 
4.  I have been anxious or worried for no good reason 
No, not at all *9   I have been so unhappy that I have been crying 
Hardly ever  Yes, most of the time 
Yes, sometimes Yes, quite often 
Yes, very often  Only occasionally 
No, never 
*5   I have felt scared or panicky for no very good reason 
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APPENDIX B 
IRB# Pro00027763 
  
Baseline Health History 
Ethnicity: _____________________ Estimated Date of Delivery “Due Date”:  _____/______/______ (MM/DD/YY)  
 
Employment:                    
Do you work outside of your home?  No 
 Yes  
Please Specify: 
How many hours do you work each week? __________ 
How many minutes does it take you to travel to work? ________________ minutes  
Please choose one of the 
following:  
Single       Partner       Living with partner        Married        Divorced 
What is your average annual income in dollars? $_________________ 
How many years of education do you currently have?________________yrs 
 
 
 
GENERAL HEALTH: THE FOLLOWING QUESTIONS ARE REGARDING YOUR GENERAL HEALTH: 
 
 
Vitals 
Ø How tall are you? _____ ft. ______ in. 
Ø How much do you currently weigh? ________ lbs. 
Ø How much did you weigh before you became pregnant? ________lbs.  
Are you currently 
taking any 
medications, 
vitamins, herbs, 
or supplements? 
Ø (Please List)________________________________________________________________________________________________________________ 
Ø ________________________________________________________________________________________________________________ 
Ø ________________________________________________________________________________________________________________ 
Exercise: 
Ø Considering a 7-Day period (a week), during your leisure-time, minutes do you spend doing  activity long enough to work up a sweat (heart beats 
rapidly)? _____________mins 
Television: Ø How many hours a day do you watch television? _________________hrs 
Computer: Ø How many hours a day do you spend on the computer? _________________hrs 
Sun Exposure: Ø How many minutes of sun exposure every day? _________________mins 
Caffeine 
Ø Do you drink caffeine?  No  Yes  
Ø Specify: Coffee  Tea  Cola  
Ø # of Cups/Cans per day:_________  
Ø Do you skip breakfast? Occasionally  Frequently  Never 
 Interviewer: __ __ 
Date: __ __ /__ __ / __ __ __ __          M  M   D  D     Y  Y   Y   Y 
Study ID#: __ __ __ __ __ __ __ __ 
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Alcohol 
Consumption 
Ø Do you currently drink alcohol?  No  Yes  
Ø On average how many drinks do you have each week? ______________ 
Tobacco Use: Ø Do you currently smoke tobacco? Daily  Less than daily   Not at all   
Drug Use:  Ø Are you currently using recreational drugs?  No  Yes 
Depression Ø Do you have a family history of depression?   No  Yes 
 
 THE FOLLOWING QUESTIONS ARE REGARDING YOUR OVERALL HEALTH 
HAVE YOU HAD ANY OF THE FOLLOWING?  
Overweight  NO  YES Chronic Bladder Infections  NO  YES 
Low levels of vitamin D  NO  YES Chronic Vaginal Infections:   NO  YES 
High blood sugar (Diabetes)  NO  YES HIV/AIDS  NO  YES 
High Cholesterol  NO  YES Syphilis  NO  YES 
Blood Disorder  NO  YES Herpes  NO  YES 
Arthritis  NO  YES Chlamydia  NO  YES 
Osteoporosis/Osteopenia  NO  YES HPV  NO  YES 
Eczema  NO  YES Gonorrhea  NO  YES 
Psoriasis  NO  YES ADD/ADHD  NO  YES 
Allergies  NO  YES Autism/Autism Spectrum  NO  YES 
Hypercalcemia  NO  YES Depression  NO  YES 
Gout  NO  YES Seasonal Affective Disorder (SADs)  NO  YES 
Fibromyalgia  NO  YES Anxiety  NO  YES 
Epilepsy  NO  YES Schizophrenia  NO  YES 
Thyroid Disease  
 
 NO  YES Bipolar Disorder  NO  YES 
Metabolic Syndrome   NO  YES Previous Preterm Labor (without preterm delivery)  NO  YES 
Hepatitis B  NO  YES Preeclampsia/Toxemia  NO  YES 
Autoimmune Diseases:  NO  YES High blood pressure during pregnancy  NO  YES 
Liver Disease  NO  YES Gestational Diabetes  NO  YES 
Parathyroid Disease  NO  YES Postpartum Depression  NO  YES 
Cushing’s Syndrome  NO  YES Group Beta Strep (GBS)  NO  YES 
Alzheimer’s Disease  NO  YES Water breaking early  NO  YES 
Eating Disorder:  NO  YES Rubella Infection  NO  YES 
Bowel Disease  NO  YES Vaginal Infection  NO  YES 
Sarcoidosis  NO  YES Anemia  NO  YES 
Periodontal Disease  NO  YES Short Cervix (Cerclage)  NO  YES 
Heart Disease  NO  YES Asthma  NO  YES 
Cancer  NO  YES High Blood Pressure  NO  YES 
Parkinson’s Disease  NO  YES 
Huntington’s Disease  NO  YES 
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CURRENT PREGNANCY AND HEALTH 
 
 
 
 
 
 
 
Renal Disease  NO  YES 
Chronic Headaches  NO  YES 
Chronic Pain  NO  YES 
Have you had the following DURING THIS PREGNANCY?   
Anemia  NO  YES 
Asthma  NO  YES 
Short Cervix (Cerclage)  NO  YES 
High Blood Pressure  NO  YES 
Vaginal Infection  NO  YES 
Bladder Infection  NO  YES 
Severe Nausea/Vomiting Requiring Hospitalization 
(Hyperemesis Gravidarium) 
 NO  YES 
Gestational Diabetes  NO  YES 
Preeclampsia  NO  YES 
Depression  NO  YES 
Group Beta Strep  NO  YES 
 
How many pregnancies have you had including miscarriages, abortions, stillbirths, AND including this pregnancy? 
 
 
How many pregnancies resulted in live births?  
How many pregnancies resulted in stillbirths (20 weeks ga)?  
How many neonatal deaths occurred (<1 month of age)?  
How many pregnancies resulted in your new baby being admitted to the NICU?  
How many pregnancies delivered preterm? (<37 weeks ga)  
How many pregnancies delivered at term?  
How many pregnancies resulted in spontaneous miscarriage? (<20 weeks ga)  
How many pregnancies resulted in induced abortion?  
How many pregnancies resulted in multiple births?  
Was the current pregnancy planned?            NO          YES 
Are you planning to breastfeed?            NO          YES 
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APPENDIX C 
Study ID : __ __ __ __   Date: ___  /___/_____ 
Depression and Vitamin D in Pregnancy Study Questionnaire 
Visit 2  
1. Current weight: _________ lbs  
2. Please circle one of the choices below: 
Single  Partner  Living with Partner Married Divorced   
 
3. Are you currently taking any medications and/or supplements (including vitamins)? 
 
• Med name: _____________________    Dose:______________    Frequency: __________ x day 
• Med name: _____________________    Dose:______________    Frequency: __________ x day 
• Med name: _____________________    Dose:______________    Frequency: __________ x day 
• Med name: _____________________    Dose:______________    Frequency: __________ x day 
• Med name: _____________________    Dose:______________    Frequency: __________ x day 
• Med name: _____________________    Dose:______________    Frequency: __________ x day 
• Med name: _____________________    Dose:______________    Frequency: __________ x day 
• Med name: _____________________    Dose:______________    Frequency: __________ x day 
 
4.   Do you have any pain currently or are you having any pain on an intermittent, ongoing 
basis?  
 
 YES      NO        
(if “yes”, continue to questions 5-12; if “no” stop) 
 
5.   How often do have the pain? 
  Constantly     Daily      Several times a week      Once a week       Less than once a 
week 
6.  During the past week has pain interfered with any of your daily activities?        YES      
NO   
7.  Rate the intensity of your pain overall:  
 
  No pain   Mild        Discomfort    Distressing    Horrible   
Excruciating 
 
8.  Does the pain affect your sleep?         YES      NO   
 
9. Does the pain have an impact on your mood?            YES      NO   
 
10. On a scale 1-10 with 10 being greatest intensity what is the overall intensity of you pain 
overall: (please circle corresponding number below) 
 
1 2 3 4 5 6 7 8 9 10 
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11.  Instructions:  For each word which describes your pain, rate the intensity of that particular 
quality of pain for each location of pain. 
  (0)   (1)  (2)    (3)           Location of Pain   
       None  Mild      Moderate Severe    Head (HA), Back, Leg, Abd., Pelvis, Incision, Breast, Perineum           
 
----------------------------------------------------------------------------------------------------------------------------------------- 
Throbbing                   HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Shooting                   HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Stabbing                   HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Sharp                   HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Cramping                   HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Gnawing                   HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Hot-burning                  HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Aching                   HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Heavy                   HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Tender                   HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Splitting                   HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Tiring-exhausting                 HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Sickening                   HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Fearful                   HA   bk   leg   abd   pel   inc   brst   peri   _____ 
 
Punishing-cruel                  HA   bk   leg   abd   pel   inc   brst   peri   _____ 
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APPENDIX D 
IRB No:  Pro00027763/ Ame00011714 
Approval Date:  12/3/2012         Expiration Date:  5/31/2013 
 
CONSENT FORM FOR RESEARCH 
RIGHTS AS A HUMAN RESEARCH PARTICIPANT  
• You have the right to make a voluntary decision to participate in this 
research study.  
• If you have questions, discuss them with the investigator before you agree to 
participate.  You have the right to ask questions at any time and have them 
answered as soon as possible. 
• You have the right to take time to review this research consent form 
carefully.  You should discuss it with others, and if appropriate seek a 
second opinion, and make an informed decision.   
• You have the right to be informed of significant new findings related to this 
research study which may affect your willingness to continue participating 
in this study.  
• You have the right not to participate or to withdraw from this research study at 
any time without any penalty or loss of benefits to which you would be entitled 
outside of the study.  Choosing so will not change the quality of care you 
receive at Cedars-Sinai Medical Center (CSMC). 
 
Depression and Vitamin D in Pregnancy Study 
  
1. WHO IS CONDUCTING THIS RESEARCH STUDY? 
 
 
Principal Investigator:   Calvin Hobel, MD  310-423-3365 
 
Co-Investigator:    Amy Lamb, PhD(c)  615-779-3001 
      
Study Coordinator:  Susan Jackman, RN  310-423-4765 
     Donnabeth Young, LVN  310-423-4788 
After hours contact:   Amy Lamb     615-779-3001 
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2. WHAT IS THE PURPOSE OF THIS RESEARCH STUDY? 
 
The purpose of the study is to understand more about mood and vitamin D 
levels in pregnancy. Previous research shows that there may be some 
relationship between vitamin D levels and mood alterations. The study will 
help us know more about how mood and vitamin D might work together. 
Lastly, the study will look at how pregnancy might influence changes in 
mood and vitamin D levels. There are no drugs involved with this study.  
 
3. WHY AM I ASKED TO PARTICIPATE? 
 
You are being asked to take part in this research study because you are a 
pregnant adult.  
 
4. HOW MANY PEOPLE WILL PARTICIPATE? 
 
About 135 people will take part in this study at CSMC. 
 
5. HOW LONG WILL I BE IN THE STUDY? 
We think you will be in the study for about 7 months, however depending on 
when you enroll and complete the study you may be in the study for as long 
as 20 months. Please see the section “What Study Procedures Are 
Involved?” for additional information. 
 
6. WHAT STUDY PROCEDURES ARE INVOLVED? 
 
This section provides a summary of procedures if you take part in this study. 
A flowchart of procedures is attached to the end of this consent form.  The 
flowchart shows a timeline for research-related or standard of care 
procedures.  Research-related procedures are those that are performed solely 
for the research.  They would not be performed if you did not take part in the 
study.  Standard of care procedures would occur even if you did not take part 
in the study. 
 
You will be asked to participate in four study visits. Your first visit will be at 
the time you are enrolled into the study, the second when you are in your 
second or third trimester, the third when you give birth to your baby, and 
finally a fourth during your postpartum period (up to one year postpartum). 
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During the first and fourth visits some blood may be collected and you will 
be asked to complete two questionnaires. During the second visit you will be 
asked to complete two questionnaires and no blood will be collected. During 
the third visit, at the time you give birth, some of your blood may be 
collected and the baby’s cord blood will be collected. Your baby will NOT 
have a blood draw as part of this study. At the end of the study we will 
review your medical record.  
 
Blood collection: 
Blood will be drawn to measure your vitamin D blood levels. Approximately 
2 teaspoons of blood will be drawn 1 time every three months, for a total of 
6 teaspoons. It may be possible to use the blood that your doctor is already 
drawing during your routine prenatal or postpartum care visits. If we are able 
to use the blood that is already being collected by your doctor then you may 
have fewer blood draws. As part of the study you will have up to 3 total 
blood draws. Cord blood will also be collected as part of this study. Extra 
cord blood will be collected during the time that routine cord blood 
collection takes place. The blood will be drawn from the umbilical cord after 
it has been separated from your baby. Less than 1 teaspoon of cord blood 
will be collected for research. Your baby will NOT receive a needle stick as 
part of this study. 
 
Questionnaires: 
You will be asked to complete two questionnaires at the first, second, and 
fourth study visits.  We will ask you questions to evaluate how you are 
feeling emotionally. We will also ask you questions about yourself (e.g. age) 
and your health (e.g. height). We think it should take about 15 minutes to 
complete the questionnaires.  Questionnaires will ask you to respond to 
questions about how you feel, if you have had thoughts of hurting yourself, 
or how much you weigh. If you feel uncomfortable or embarrassed 
answering any question, you may skip it. The questionnaire will be labeled 
with a unique study number that will link your identity so that only the 
research team can recognize you.  
 
Medical Records: 
Your medical history will be reviewed at the end of the study. It will be 
necessary to review your records in order to make sure the data collected 
about you as part of the study is correct.  
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7. WHAT ARE THE POSSIBLE RISKS OR DISCOMFORTS? 
 
There might be some possible risks or discomforts associated with taking 
part in this study. You may experience feelings of embarrassment or a loss 
of confidentiality as a result of answering questions about how you feel and 
having your medical record reviewed. If you note having thoughts of self-
harm when responding to study questionnaires you will be referred to the 
emergency room and your physician will be notified. At the completion of 
the study when the questionnaires are analyzed if you have severely elevated 
depressive symptoms then you and your physician will be notified.  
 
Blood Draw 
Blood drawing may cause some pain and has a small risk of bleeding, 
bruising, or infection at the puncture site.  There is also a small risk of 
fainting. 
 
Incidental Findings 
It is possible that the study procedures could detect a possible medical 
problem that is unrelated to the purpose of this study that was previously 
unknown.  If the research procedures uncover findings that may be 
important for you to know about, such as the possibility of a previously 
unknown medical condition, you will be informed by a member of the 
research team. Or, you may authorize the release and communication of the 
findings to your primary physician.  These findings may require additional 
testing or treatment.  The cost of any additional tests or related treatment 
will be your responsibility.  
 
Because we do not yet know what different vitamin D levels mean for 
pregnant women and their babies, and this is not a standard test done in 
clinical care for pregnant women or their babies, we will not inform you or 
your primary physician of the findings regarding your vitamin D levels 
during the course of the study. However, at the completion of the study 
when vitamin D levels are analyzed we will inform you and your physician 
if you or your baby’s levels are very low or high.  
  
8. ARE THERE DIRECT BENEFITS IN TAKING PART IN THE 
STUDY? 
 
You should not expect to benefit directly from taking part in this research 
study. 
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9. HOW CAN MY PARTICIPATION BENEFIT OTHERS?  
 
While no benefit is ever guaranteed, we hope the information learned from 
this research study will benefit other pregnant women and babies in the 
future by helping us to learn more about how mood and vitamin D might 
influence each other in pregnancy. It may also help us know more about the 
role that vitamin D has in pregnancy. Finally, there is a small possibility that 
it may give us knowledge to help reduce the risk for developing depression 
in pregnancy and postpartum.  
 
10. WHY WOULD MY PARTICIPATION BE STOPPED? 
 
The investigator may decide to take you off this research study for any 
reason, even if you would like to continue.  Some examples of why the 
investigator might take you off the study include the following: the 
investigator determines that it is in your best medical interest; your condition 
worsens; funding for the study is stopped; the whole study is stopped or 
modified at CSMC or at all sites for any reason; or you are unable to comply 
with the protocol.  
 
You may also decide to withdraw from the research study at any time. 
However, the researchers may continue to analyze data previously collected 
from you before you withdrew from the research study. 
 
11. ARE THERE ANY OTHER OPTIONS? 
 
Your participation is voluntary and you can choose to not participate in this 
study.  Your medical care will not be changed in any way as a result of this 
decision. 
 
12. HOW WILL MY PRIVATE INFORMATION BE KEPT 
CONFIDENTIAL? 
 
CSMC values and respects your private information.  Federal and state laws 
protect your privacy.  Every reasonable effort will be made to keep your 
records confidential, such as storing your private information in a secure 
location where only authorized individuals will have access to it.  When 
possible, investigators will assign a unique code to your research 
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information so that people who see the coded data will not be able to 
identify you.   
  
If information from this study is published, presented at scientific meetings, 
or used for teaching, your name and other personal information will not be 
used. 
 
People inside and outside of CSMC may need to see your information for 
this study.  Information collected about you during the course of this 
research may be subject to inspection by accrediting agencies, government 
and regulatory groups (e.g. Food and Drug Administration (FDA), Office for 
Human Research Protections (OHRP), etc.), safety monitors, and companies 
that sponsor the study. These agencies are responsible for the oversight of 
this research.  You will be asked to sign a separate “Authorization Form” 
that outlines who your information may be shared with for the purposes of 
this research and under what circumstances.   
 
 
 
13. WHAT ARE THE COSTS OF TAKING PART IN THIS 
STUDY? 
 
You and your insurance company will not be charged for your participation 
in this research study. 
 
14. WILL I BE PAID? 
 
You will receive a $10 gift card at the first visit and a $10 gift card at the 
end of the study. The total amount you will receive if you complete the 
whole study is $20 dollars in gift cards. If you do not complete the entire 
research study, you will only be paid for those visits and procedures you do 
complete. For any visits you make to the study office you will be reimbursed 
for parking. You may be required to complete a W-9 Form in order to 
receive payment.  The W-9 Form will be maintained by our accounting 
department at CSMC.  If payment exceeds $600 in a calendar year, a 1099 
Form will be filed with the IRS in accordance with federal tax law.  
 
If you are a CSMC employee, you should provide your employee 
identification number to the research team so that your payment can be 
appropriately processed through Payroll.  For your own protection and to 
   
117 
comply with tax laws, your payment for participation will be reported to the 
IRS together with other compensation you receive from CSMC. 
 
 
15. WHAT IF I BECOME ILL OR INJURED BECAUSE OF 
TAKING PART IN THIS STUDY? 
 
You will not be in danger of any illness or injury from this research study.  
However, should you believe that you are ill or have been injured as a result 
of your participation, please contact the Co-Investigator listed on the first 
page of this consent form, under  “Who Is Conducting This Research 
Study?” 
 
 
16. WHAT IF I HAVE QUESTIONS OR PROBLEMS? 
 
If you have questions or concerns about this research, please contact the Co-
investigator or Principal Investigator listed under “Who is conducting this 
research study?” on the first page of this consent form.   
 
If you have questions regarding your rights, concerns, or complaints about 
taking part in this study, please contact: 
 
CSMC Institutional Review Board (IRB) 
Phone: (310) 423-3783 
Email: ResearchConcerns@cshs.org 
 
The CSMC IRB has been established to review, approve, and monitor all 
human research at CSMC with the purpose of minimizing risks and 
protecting the rights and welfare of research participants. 
 
Permission to be contacted in the future 
 
If you agree, you will be contacted in the future to receive information on 
other research studies investigating vitamin D, depression, or other 
pregnancy complications. 
 
 
 YES  NO I agree to be contacted in the future to receive information 
on other research studies investigating vitamin D, 
depression, or other pregnancy complications. 
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17.     CONSENT PROVISIONS  
 
If you sign this form below, it means that:   
 
(1) You have carefully read and understood the information presented in 
this informed consent form;  
(2) The information concerning the research study and its involved 
procedures has been fully explained to you and your questions have been 
answered to your satisfaction;  
(3) You have received all of the information you desire regarding your 
participation in the research study;  
(4) You have considered the potential risks, anticipated benefits and 
alternatives (and their relative risks and benefits) of participation; 
(5) You are voluntarily agreeing to participate in this research study; 
(6) For research where you will receive treatment or diagnostic intervention, 
you agree that your right to access copies of health information created 
during your participation in your research will be suspended while the 
research study is in progress; your right to access this information will be 
restored upon completion of the entire study; 
(7) You understand that by consenting to participate in the research, you are 
not giving up any of your legal rights (other than the postponement of your 
access to certain health information as described in this informed consent 
form); and 
 (8) You have been provided with a copy of the “Experimental Subject’s 
Bill of Rights”, if applicable to this research study, and have been provided 
with an opportunity to ask questions regarding the Bill of Rights. 
 
If you have any additional questions during the course of your involvement 
in the research, please contact the investigator(s) and/or the IRB Office at 
any time. 
 
We will give you a copy of this signed and dated consent form. 
 
SIGNATURE BY THE SUBJECT: 
 
 
      
Name of Subject (Print) Signature of Subject Date of 
Signature 
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SIGNATURE BY THE INVESTIGATOR: 
 
I attest that all the elements of informed consent described in this form 
have been discussed fully in non-technical terms with the subject.  I further 
attest that all questions asked by the subject were answered to the best of 
my knowledge.    
 
 
    
Signature of the Investigator Who Obtained Consent Date of 
Signature 
 
 
SIGNATURE BY THE WITNESS/TRANSLATOR  
(Signature of a witness is only required when a non-English speaking 
subject is consented with the assistance of a translator and an IRB-
approved ‘short form.’  The signature of the witness below attests that the 
translator has presented the elements of consent to the subject, orally and 
in his/her preferred language, and that a summary of the oral presentation, 
in a language the subject can understand, has been given to the 
participant.) 
 
 
    
Signature of Witness  Date of Signature 
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EXPERIMENTAL SUBJECT’S BILL OF RIGHTS 
In accordance with California Health and Safety Code 24172, any person 
who is required to consent to participate as a subject in a research study 
involving a medical experiment or who is requested to consent on behalf of 
another has the right to: 
 
1. Be informed of the nature and purpose of the experiment. 
 
2. Be given an explanation of the procedures to be followed in the 
medical experiment, and any drug or device to be utilized. 
 
3. Be given a description of any attendant discomforts and risks to the 
subject reasonably to be expected from the experiment. 
 
4. Be given an explanation of any benefits to the subject reasonably to be 
expected from the experiment, if applicable. 
 
5. Be given a disclosure of any appropriate alternative procedures, drugs 
or devices that might be advantageous to the subject, and their relative 
risks and benefits. 
 
6. Be informed of the avenues of medical treatment, if any, available to 
the subject after the experiment if complications should arise. 
 
7. Be given an opportunity to ask any questions concerning the 
experiment or the procedure involved. 
 
8. Be instructed that consent to participate in the medical experiment 
may be withdrawn at any time and the subject may discontinue 
participation in the medical experiment without prejudice. 
 
9. Be given a copy of any signed and dated written consent form used in 
relation to the experiment. 
 
10. Be given the opportunity to decide to consent or not to consent to a 
medical experiment without the intervention of any element of force, 
fraud, deceit, duress, coercion, or undue influence on the subject’s 
decision. 
 
 
 ___________________________________________    _______________________ 
Signature of Experimental Subject    Date 
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Distribution instruction for investigators: 
 
The signed (i) Consent form, (ii) Authorization for Use and Disclosure of 
Identifiable Health Information and (iii) "Experimental Subject’s Bill of 
Rights" (the latter required if the research study involves medical 
interventions)* should be distributed to: 
 
1) Medical Chart 
2) Subject 
3) Principal Investigator’s research records (original) 
 
 
FLOWCHART OF PROCEDURES  
 
Procedures Visit 
#1 
Visit 
#2 
Visit 
#3 
Visit 
#4 
Research Related Procedures: Procedures, 
drugs, devices, evaluations or other services 
done only because of your participation in 
this research. 
    
Review of your medical records by the 
study team 
   X 
Blood draw to measure Vitamin D Levels  X*  X* X* 
Completion of 2 questionnaires: 
Depression Scale and  Demographic and 
Clinical Obstetric Information 
Questionnaire 
X X  X 
Collection of Cord Blood   X*  
 
 
* As necessary. If we are able to use the blood that is already being 
collected by your doctor, then you may have fewer blood draws. As part 
of the study you will have up to 3 total blood draws. 
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